{
  "tgct": {
    "regimen_groups": [],
    "unmet_need_signals": [],
    "novel_studies": {
      "columns": [
        "Identifier",
        "Title",
        "Speakers",
        "Affiliation"
      ],
      "rows": [
        {
          "Identifier": "2694P",
          "Title": "Long-term efficacy and safety of vimseltinib in patients (pts) with tenosynovial giant cell tumor (TGCT): 2-year results from the MOTION phase III trial",
          "Speakers": "Sebastian Bauer",
          "Affiliation": "German Cancer Consortium, Partner Site University Hospital Essen, Essen, Germany."
        },
        {
          "Identifier": "2690MO",
          "Title": "Extended efficacy and safety from the phase III MANEUVER trial of pimicotinib in patients with tenosynovial giant cell tumour (TGCT)",
          "Speakers": "Xiaohui Niu",
          "Affiliation": "Department of Orthopaedic Oncology Surgery, National Center for Orthopedics, Beijing Jishuitan Hospital, Capital Medical University, Beijing, China."
        }
      ]
    },
    "table_context": "**NOVEL/EARLY-PHASE STUDIES:**\n| Identifier   | Title                                                                                                                                                    | Speakers        | Affiliation                                                                                                                                          |\n|:-------------|:---------------------------------------------------------------------------------------------------------------------------------------------------------|:----------------|:-----------------------------------------------------------------------------------------------------------------------------------------------------|\n| 2694P        | Long-term efficacy and safety of vimseltinib in patients (pts) with tenosynovial giant cell tumor (TGCT): 2-year results from the MOTION phase III trial | Sebastian Bauer | German Cancer Consortium, Partner Site University Hospital Essen, Essen, Germany.                                                                    |\n| 2690MO       | Extended efficacy and safety from the phase III MANEUVER trial of pimicotinib in patients with tenosynovial giant cell tumour (TGCT)                     | Xiaohui Niu     | Department of Orthopaedic Oncology Surgery, National Center for Orthopedics, Beijing Jishuitan Hospital, Capital Medical University, Beijing, China. |\n"
  },
  "bladder_cancer": {
    "regimen_groups": [
      {
        "regimen": "EV+Pembrolizumab",
        "count": 10,
        "examples": [
          "LBA2",
          "3094P",
          "3089P",
          "3102P",
          "3073P"
        ]
      },
      {
        "regimen": "Durvalumab",
        "count": 5,
        "examples": [
          "3084P",
          "3121eP",
          "LBA108",
          "3069MO",
          "3106P"
        ]
      },
      {
        "regimen": "Nivolumab",
        "count": 3,
        "examples": [
          "LBA110",
          "1513O",
          "3068O"
        ]
      }
    ],
    "unmet_need_signals": [
      {
        "category": "Post-progression",
        "count": 2
      },
      {
        "category": "Elderly patients",
        "count": 2
      },
      {
        "category": "Brain metastases",
        "count": 1
      }
    ],
    "biomarker_moa": {
      "columns": [
        "Biomarker/MOA",
        "# Studies",
        "Identifiers",
        "Sessions"
      ],
      "rows": [
        {
          "Biomarker/MOA": "Nectin-4",
          "# Studies": 4,
          "Identifiers": "967P, 3095P, 3100P, 3105P",
          "Sessions": "Poster"
        },
        {
          "Biomarker/MOA": "FGFR3",
          "# Studies": 3,
          "Identifiers": "3070MO, 3102P, 3098P",
          "Sessions": "Mini Oral Session, Poster"
        },
        {
          "Biomarker/MOA": "HER2",
          "# Studies": 2,
          "Identifiers": "LBA7, 3079P",
          "Sessions": "Proffered Paper, Poster"
        },
        {
          "Biomarker/MOA": "ERBB2",
          "# Studies": 2,
          "Identifiers": "3102P, 3095P",
          "Sessions": "Poster"
        },
        {
          "Biomarker/MOA": "ctDNA",
          "# Studies": 2,
          "Identifiers": "3068O, 3110eP",
          "Sessions": "Proffered Paper, ePoster"
        },
        {
          "Biomarker/MOA": "PD-L1",
          "# Studies": 1,
          "Identifiers": "3128eP",
          "Sessions": "ePoster"
        },
        {
          "Biomarker/MOA": "FGFR",
          "# Studies": 1,
          "Identifiers": "1766eP",
          "Sessions": "ePoster"
        }
      ]
    },
    "novel_studies": {
      "columns": [
        "Identifier",
        "Title",
        "Speakers",
        "Affiliation"
      ],
      "rows": [
        {
          "Identifier": "3070MO",
          "Title": "Phase I study of LY3866288, a potent, highly isoform-selective FGFR3 inhibitor in FGFR3-altered advanced solid tumors (FORAGER-1): Dose optimization",
          "Speakers": "Alexandra Drakaki",
          "Affiliation": "19University of California, Los Angeles Medical Center, CA, USA."
        },
        {
          "Identifier": "3083P",
          "Title": "JAVELIN bladder medley phase II trial of avelumab + sacituzumab govitecan (Ave + SG) vs avelumab monotherapy (Ave mono) as first-line (1L) maintenance treatment for advanced urothelial carcinoma (aUC): Subgroup analyses based on metastatic sites",
          "Speakers": "Begona Perez Valderrama",
          "Affiliation": "Oncology Department, Hospital Universitario Virgen del Rocio, Sevilla, Spain."
        },
        {
          "Identifier": "3085P",
          "Title": "PUNCH02: Interim results from a phase II study of tislelizumab combined with disitamab vedotin as a bladder preservation therapy for urine tumor DNA (utDNA)-defined clinical complete response (cCR) MIBC patients",
          "Speakers": "Bin Huang",
          "Affiliation": "Department of Urology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou"
        },
        {
          "Identifier": "967P",
          "Title": "Phase I/II study of the next-generation Nectin-4-targeting antibodydrug conjugate CRB-701 (SYS6002) in patients with urothelial and non-urothelial solid tumours",
          "Speakers": "Cesar A. Perez",
          "Affiliation": "Sarah Cannon Research Institute at Florida Cancer Specialists, Orlando, FL, USA."
        },
        {
          "Identifier": "3084P",
          "Title": "Durvalumab (D) +/- tremelimumab (T) in combination with dose-dense MVAC (ddMVAC) as neoadjuvant treatment in patients with muscle-invasive bladder carcinoma (MIBC): Updated results (EFS and OS) of NEMIO, a phase I/II trial",
          "Speakers": "Constance Thibault",
          "Affiliation": "Department of Medical Oncology, Georges Pompidou European Hospital, AP-HP, Paris Cité University, Paris, France."
        },
        {
          "Identifier": "",
          "Title": "Novel imaging",
          "Speakers": "Elena Verzoni",
          "Affiliation": "Department of Medical Oncology, Milan, Italy."
        },
        {
          "Identifier": "",
          "Title": "LBA 109 - DISCUS: A phase II study comparing 3 vs 6 cycles of platinum-based chemotherapy prior to maintenance avelumab in advanced urothelial cancer.",
          "Speakers": "Enrique Grande",
          "Affiliation": ""
        },
        {
          "Identifier": "",
          "Title": "Novel ADCs",
          "Speakers": "Enrique Grande",
          "Affiliation": ""
        },
        {
          "Identifier": "3088P",
          "Title": "Association of molecular markers with clinical response to TAR-200 in the phase IIb SunRISe-1 trial in patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with or without papillary disease",
          "Speakers": "Felix Guerrero-Ramos",
          "Affiliation": "Department of Urology, Hospital Universitario 12 de Octubre, Madrid, Spain."
        },
        {
          "Identifier": "3078P",
          "Title": "Immune-mediated adverse events (imAEs) associated with sasanlimab in combination with Bacillus Calmette-Guerin (BCG): Phase III study (CREST)",
          "Speakers": "Jens Bedke",
          "Affiliation": "Department of Urology and Transplantation Surgery, Eva Mayr-Stihl Cancer Center, Stuttgart, Germany."
        },
        {
          "Identifier": "3071MO",
          "Title": "Disitamab vedotin plus tislelizumab as nephron-sparing therapy for high-risk upper tract urothelial carcinoma: The phase II DISTINCT-I trial",
          "Speakers": "Jiwei Huang",
          "Affiliation": "Department of Urology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China."
        },
        {
          "Identifier": "3092P",
          "Title": "Impact of dose reductions on the efficacy of erdafitinib (Erda) in patients (Pts) with advanced or metastatic urothelial carcinoma (mUC): A post-hoc analysis of the phase III THOR study cohort-1 evaluating Erda versus chemotherapy (Chemo)",
          "Speakers": "Patrizia Giannatempo",
          "Affiliation": "Department of Medical Oncology, Fondazione IRCCS, Milan, Italy."
        },
        {
          "Identifier": "3135eTiP",
          "Title": "INTerpath-011: Phase II study of intismeran autogene (V940/mRNA-4157) plus bacillus Calmette-Guerin (BCG) versus BCG alone for high-risk (HR) nonmuscle-invasive bladder cancer (NMIBC)",
          "Speakers": "Petros Grivas",
          "Affiliation": "University of Washington Medical Center, Fred Hutchinson Cancer Center, Seattle, WA, USA."
        },
        {
          "Identifier": "3106P",
          "Title": "Perioperative chemo-immunotherapy with Durvalumab for operable muscle-invasive urothelial carcinoma (MIUC): Final analysis of the single arm phase II trial SAKK 06/17",
          "Speakers": "Richard Cathomas",
          "Affiliation": "Department of Medical Oncology, Kantonsspital Graubünden, Chur, Switzerland."
        },
        {
          "Identifier": "3072MO",
          "Title": "Datopotamab deruxtecan (Dato-DXd) + rilvegostomig (rilve) in patients (pts) with locally advanced or metastatic urothelial cancer (a/mUC): Results from the phase II TROPION-PanTumor03 study",
          "Speakers": "Sun Young Rha",
          "Affiliation": "Yonsei Cancer Center, Yonsei University College of Medicine, Yonsei University Health System, Seoul, Republic of Korea."
        },
        {
          "Identifier": "3086P",
          "Title": "A phase II Study of organ-preserving therapy and liquid biopsy-based response monitoring in locally advanced muscle-invasive bladder cancer",
          "Speakers": "Yali Shen",
          "Affiliation": "Division of Abdominal Tumor Multimodality Treatment, Department of Radiation Oncology, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan"
        },
        {
          "Identifier": "3103P",
          "Title": "Chemotherapy plus Toripalimab as neoadjuvant therapy for locally advanced upper tract urothelial carcinoma: Mid-term results from the phase II, multi-center study (WUTSUP-01)",
          "Speakers": "Yige Bao",
          "Affiliation": "Department of Urology, West China Hospital Sichuan University, Chengdu"
        },
        {
          "Identifier": "3081P",
          "Title": "Bladder preservation therapy in combination with atezolizumab and radiation therapy (BPT-ART) for invasive bladder cancer: Final analysis from a multicenter, open-label, prospective phase II trial",
          "Speakers": "Yoshiyuki Nagumo",
          "Affiliation": "Department of Urology, University of Tsukuba Institute of Medicine, Tsukuba, Ibaraki, Japan."
        }
      ]
    },
    "table_context": "**BIOMARKER/MOA TABLE:**\n| Biomarker/MOA   |   # Studies | Identifiers               | Sessions                  |\n|:----------------|------------:|:--------------------------|:--------------------------|\n| Nectin-4        |           4 | 967P, 3095P, 3100P, 3105P | Poster                    |\n| FGFR3           |           3 | 3070MO, 3102P, 3098P      | Mini Oral Session, Poster |\n| HER2            |           2 | LBA7, 3079P               | Proffered Paper, Poster   |\n| ERBB2           |           2 | 3102P, 3095P              | Poster                    |\n| ctDNA           |           2 | 3068O, 3110eP             | Proffered Paper, ePoster  |\n| PD-L1           |           1 | 3128eP                    | ePoster                   |\n| FGFR            |           1 | 1766eP                    | ePoster                   |\n\n**NOVEL/EARLY-PHASE STUDIES:**\n| Identifier   | Title                                                                                                                                                                                                                                                 | Speakers                | Affiliation                                                                                                                                                                                            |\n|:-------------|:------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|:------------------------|:-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n| 3070MO       | Phase I study of LY3866288, a potent, highly isoform-selective FGFR3 inhibitor in FGFR3-altered advanced solid tumors (FORAGER-1): Dose optimization                                                                                                  | Alexandra Drakaki       | 19University of California, Los Angeles Medical Center, CA, USA.                                                                                                                                       |\n| 3083P        | JAVELIN bladder medley phase II trial of avelumab + sacituzumab govitecan (Ave + SG) vs avelumab monotherapy (Ave mono) as first-line (1L) maintenance treatment for advanced urothelial carcinoma (aUC): Subgroup analyses based on metastatic sites | Begona Perez Valderrama | Oncology Department, Hospital Universitario Virgen del Rocio, Sevilla, Spain.                                                                                                                          |\n| 3085P        | PUNCH02: Interim results from a phase II study of tislelizumab combined with disitamab vedotin as a bladder preservation therapy for urine tumor DNA (utDNA)-defined clinical complete response (cCR) MIBC patients                                   | Bin Huang               | Department of Urology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou                                                                                                              |\n| 967P         | Phase I/II study of the next-generation Nectin-4-targeting antibodydrug conjugate CRB-701 (SYS6002) in patients with urothelial and non-urothelial solid tumours                                                                                      | Cesar A. Perez          | Sarah Cannon Research Institute at Florida Cancer Specialists, Orlando, FL, USA.                                                                                                                       |\n| 3084P        | Durvalumab (D) +/- tremelimumab (T) in combination with dose-dense MVAC (ddMVAC) as neoadjuvant treatment in patients with muscle-invasive bladder carcinoma (MIBC): Updated results (EFS and OS) of NEMIO, a phase I/II trial                        | Constance Thibault      | Department of Medical Oncology, Georges Pompidou European Hospital, AP-HP, Paris Cité University, Paris, France.                                                                                       |\n|              | Novel imaging                                                                                                                                                                                                                                         | Elena Verzoni           | Department of Medical Oncology, Milan, Italy.                                                                                                                                                          |\n|              | LBA 109 - DISCUS: A phase II study comparing 3 vs 6 cycles of platinum-based chemotherapy prior to maintenance avelumab in advanced urothelial cancer.                                                                                                | Enrique Grande          |                                                                                                                                                                                                        |\n|              | Novel ADCs                                                                                                                                                                                                                                            | Enrique Grande          |                                                                                                                                                                                                        |\n| 3088P        | Association of molecular markers with clinical response to TAR-200 in the phase IIb SunRISe-1 trial in patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with or without papillary disease      | Felix Guerrero-Ramos    | Department of Urology, Hospital Universitario 12 de Octubre, Madrid, Spain.                                                                                                                            |\n| 3078P        | Immune-mediated adverse events (imAEs) associated with sasanlimab in combination with Bacillus Calmette-Guerin (BCG): Phase III study (CREST)                                                                                                         | Jens Bedke              | Department of Urology and Transplantation Surgery, Eva Mayr-Stihl Cancer Center, Stuttgart, Germany.                                                                                                   |\n| 3071MO       | Disitamab vedotin plus tislelizumab as nephron-sparing therapy for high-risk upper tract urothelial carcinoma: The phase II DISTINCT-I trial                                                                                                          | Jiwei Huang             | Department of Urology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.                                                                                             |\n| 3092P        | Impact of dose reductions on the efficacy of erdafitinib (Erda) in patients (Pts) with advanced or metastatic urothelial carcinoma (mUC): A post-hoc analysis of the phase III THOR study cohort-1 evaluating Erda versus chemotherapy (Chemo)        | Patrizia Giannatempo    | Department of Medical Oncology, Fondazione IRCCS, Milan, Italy.                                                                                                                                        |\n| 3135eTiP     | INTerpath-011: Phase II study of intismeran autogene (V940/mRNA-4157) plus bacillus Calmette-Guerin (BCG) versus BCG alone for high-risk (HR) nonmuscle-invasive bladder cancer (NMIBC)                                                               | Petros Grivas           | University of Washington Medical Center, Fred Hutchinson Cancer Center, Seattle, WA, USA.                                                                                                              |\n| 3106P        | Perioperative chemo-immunotherapy with Durvalumab for operable muscle-invasive urothelial carcinoma (MIUC): Final analysis of the single arm phase II trial SAKK 06/17                                                                                | Richard Cathomas        | Department of Medical Oncology, Kantonsspital Graubünden, Chur, Switzerland.                                                                                                                           |\n| 3072MO       | Datopotamab deruxtecan (Dato-DXd) + rilvegostomig (rilve) in patients (pts) with locally advanced or metastatic urothelial cancer (a/mUC): Results from the phase II TROPION-PanTumor03 study                                                         | Sun Young Rha           | Yonsei Cancer Center, Yonsei University College of Medicine, Yonsei University Health System, Seoul, Republic of Korea.                                                                                |\n| 3086P        | A phase II Study of organ-preserving therapy and liquid biopsy-based response monitoring in locally advanced muscle-invasive bladder cancer                                                                                                           | Yali Shen               | Division of Abdominal Tumor Multimodality Treatment, Department of Radiation Oncology, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan |\n| 3103P        | Chemotherapy plus Toripalimab as neoadjuvant therapy for locally advanced upper tract urothelial carcinoma: Mid-term results from the phase II, multi-center study (WUTSUP-01)                                                                        | Yige Bao                | Department of Urology, West China Hospital Sichuan University, Chengdu                                                                                                                                 |\n| 3081P        | Bladder preservation therapy in combination with atezolizumab and radiation therapy (BPT-ART) for invasive bladder cancer: Final analysis from a multicenter, open-label, prospective phase II trial                                                  | Yoshiyuki Nagumo        | Department of Urology, University of Tsukuba Institute of Medicine, Tsukuba, Ibaraki, Japan.                                                                                                           |\n"
  },
  "lung_cancer": {
    "regimen_groups": [
      {
        "regimen": "Osimertinib",
        "count": 25,
        "examples": [
          "2064eP",
          "1817MO",
          "1966P",
          "1960P",
          "1963P"
        ]
      },
      {
        "regimen": "Alectinib",
        "count": 7,
        "examples": [
          "1828P",
          "1983P",
          "996P",
          "1787MO",
          "LBA73"
        ]
      },
      {
        "regimen": "Amivantamab",
        "count": 6,
        "examples": [
          "1966P",
          "1960P",
          "2082eTiP",
          "37eP",
          "932P"
        ]
      },
      {
        "regimen": "Tepotinib",
        "count": 3,
        "examples": [
          "1996P",
          "1995P",
          "1998P"
        ]
      }
    ],
    "unmet_need_signals": [
      {
        "category": "Post-progression",
        "count": 31
      },
      {
        "category": "Brain metastases",
        "count": 21
      },
      {
        "category": "Resistance mechanisms",
        "count": 18
      },
      {
        "category": "Sequencing strategies",
        "count": 17
      },
      {
        "category": "Elderly patients",
        "count": 4
      },
      {
        "category": "Poor performance status",
        "count": 2
      },
      {
        "category": "Rare mutations",
        "count": 2
      }
    ],
    "biomarker_moa": {
      "columns": [
        "Biomarker/MOA",
        "# Studies",
        "Identifiers",
        "Sessions"
      ],
      "rows": [
        {
          "Biomarker/MOA": "EGFR",
          "# Studies": 68,
          "Identifiers": "1948P, 853P, 677P, 2071eP, 891eP, LBA33, 3029eP, 2064eP, 249eP, , +58 more",
          "Sessions": "Poster, ePoster, Proffered Paper, +2 more"
        },
        {
          "Biomarker/MOA": "BRAF",
          "# Studies": 43,
          "Identifiers": "2996P, 853P, 1682P, 891eP, , 687P, 1646P, , 2991P, 803P, +33 more",
          "Sessions": "Poster, ePoster, Industry-Sponsored S, +2 more"
        },
        {
          "Biomarker/MOA": "KRAS",
          "# Studies": 33,
          "Identifiers": "LBA84, 1016eTiP, 265eP, 1990P, 915O, , 1992P, 3029eP, 882eP, 743P, +23 more",
          "Sessions": "Proffered Paper, ePoster, Poster, +3 more"
        },
        {
          "Biomarker/MOA": "PD-L1",
          "# Studies": 25,
          "Identifiers": "1879P, 1795P, 2021P, 1851MO, 1886P, 1962P, 1869P, 1920P, 255eP, 2025TiP, +15 more",
          "Sessions": "Poster, Mini Oral Session, ePoster, +1 more"
        },
        {
          "Biomarker/MOA": "ALK",
          "# Studies": 23,
          "Identifiers": "972P, 1984P, 1828P, 1983P, LBA66, 996P, 1982P, 2567P, , 1979P, +13 more",
          "Sessions": "Poster, Mini Oral Session, Industry-Sponsored S, +2 more"
        },
        {
          "Biomarker/MOA": "MET",
          "# Studies": 16,
          "Identifiers": "928P, 2074eP, 995P, 1795P, 1996P, 1967P, 1997P, 2610MO, 1955P, 932P, +6 more",
          "Sessions": "Poster, ePoster, Mini Oral Session, +1 more"
        },
        {
          "Biomarker/MOA": "ctDNA",
          "# Studies": 15,
          "Identifiers": "2783P, 1893P, 1819P, 1957P, LBA70, 2020P, 1913P, LBA32, 190eP, 125P, +5 more",
          "Sessions": "Poster, Mini Oral Session, Proffered Paper, +1 more"
        },
        {
          "Biomarker/MOA": "HER2",
          "# Studies": 10,
          "Identifiers": ", 2002P, 2020P, 540P, 2058eP, 2001P, LBA74, 2003P, LBA75, 738P",
          "Sessions": "Industry-Sponsored S, Poster, ePoster, +1 more"
        },
        {
          "Biomarker/MOA": "PD-1",
          "# Studies": 6,
          "Identifiers": "1853MO, 2021P, 18P, 1898P, 1938P, 1933P",
          "Sessions": "Mini Oral Session, Poster"
        },
        {
          "Biomarker/MOA": "NTRK",
          "# Studies": 4,
          "Identifiers": "2013P, 171P, 687P, 2998P",
          "Sessions": "Poster"
        },
        {
          "Biomarker/MOA": "ROS1",
          "# Studies": 4,
          "Identifiers": "1988P, 1986P, 2027TiP, 1987MO",
          "Sessions": "Poster, Mini Oral Session"
        },
        {
          "Biomarker/MOA": "DLL3",
          "# Studies": 4,
          "Identifiers": ", 2776P, , 2775P",
          "Sessions": "Industry-Sponsored S, Poster"
        },
        {
          "Biomarker/MOA": "TIGIT",
          "# Studies": 3,
          "Identifiers": "1853MO, 3061eP, 1885P",
          "Sessions": "Mini Oral Session, ePoster, Poster"
        },
        {
          "Biomarker/MOA": "RET",
          "# Studies": 3,
          "Identifiers": "1999P, 2000P, 2998P",
          "Sessions": "Poster"
        },
        {
          "Biomarker/MOA": "VEGF",
          "# Studies": 3,
          "Identifiers": "1860P, 792P, 875eP",
          "Sessions": "Poster, ePoster"
        },
        {
          "Biomarker/MOA": "HER3",
          "# Studies": 2,
          "Identifiers": "921MO, 933P",
          "Sessions": "Mini Oral Session, Poster"
        },
        {
          "Biomarker/MOA": "FGFR",
          "# Studies": 2,
          "Identifiers": "1931P, 1932P",
          "Sessions": "Poster"
        },
        {
          "Biomarker/MOA": "CTC",
          "# Studies": 2,
          "Identifiers": "190eP, 1813eP",
          "Sessions": "ePoster"
        },
        {
          "Biomarker/MOA": "FGFR1",
          "# Studies": 1,
          "Identifiers": "2067eP",
          "Sessions": "ePoster"
        },
        {
          "Biomarker/MOA": "CTLA-4",
          "# Studies": 1,
          "Identifiers": "18P",
          "Sessions": "Poster"
        },
        {
          "Biomarker/MOA": "LAG-3",
          "# Studies": 1,
          "Identifiers": "1857P",
          "Sessions": "Poster"
        },
        {
          "Biomarker/MOA": "TMB",
          "# Studies": 1,
          "Identifiers": "1980P",
          "Sessions": "Poster"
        },
        {
          "Biomarker/MOA": "MSI",
          "# Studies": 1,
          "Identifiers": "886eP",
          "Sessions": "ePoster"
        },
        {
          "Biomarker/MOA": "dMMR",
          "# Studies": 1,
          "Identifiers": "886eP",
          "Sessions": "ePoster"
        },
        {
          "Biomarker/MOA": "MSI-H",
          "# Studies": 1,
          "Identifiers": "886eP",
          "Sessions": "ePoster"
        },
        {
          "Biomarker/MOA": "PARP",
          "# Studies": 1,
          "Identifiers": "157P",
          "Sessions": "Poster"
        },
        {
          "Biomarker/MOA": "PIK3CA",
          "# Studies": 1,
          "Identifiers": "846P",
          "Sessions": "Poster"
        },
        {
          "Biomarker/MOA": "NRG1",
          "# Studies": 1,
          "Identifiers": "1993P",
          "Sessions": "Poster"
        },
        {
          "Biomarker/MOA": "ERBB2",
          "# Studies": 1,
          "Identifiers": "2003P",
          "Sessions": "Poster"
        }
      ]
    },
    "novel_studies": {
      "columns": [
        "Identifier",
        "Title",
        "Speakers",
        "Affiliation"
      ],
      "rows": [
        {
          "Identifier": "1016eTiP",
          "Title": "A first-in-human phase I study of LY4066434, a potent and orally bioavailable pan-KRAS inhibitor, in KRAS-mutant solid tumors (Trial in Progress)",
          "Speakers": "Shigehisa Kitano",
          "Affiliation": "Department of Advanced Medical Development, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan."
        },
        {
          "Identifier": "2023P",
          "Title": "Phase Ib study of valemetostat in combination with datopotamab deruxtecan (Dato-DXd) in advanced non-squamous non-small cell lung cancer (NSCLC): Initial safety results",
          "Speakers": "Alexander I. Spira",
          "Affiliation": "Virginia Cancer Specialists, Fairfax, VA, USA."
        },
        {
          "Identifier": "853P",
          "Title": "Landscape of anti-EGFR resistance mutations in RAS/BRAF-wild type left-sided metastatic colorectal cancer: First sequencing results of the phase III CRC01 prospective trial",
          "Speakers": "Alexandra Lebedeva",
          "Affiliation": "Institute for Personalized Oncology, Sechenov First Moscow State Medical University, Moscow 119048, Russia."
        },
        {
          "Identifier": "1947P",
          "Title": "Phase II study of sacituzumab govitecan (SG), domvanalimab (dom), and zimberelimab (zim) in metastatic non-small cell lung cancer (mNSCLC): VELOCITY-Lung substudy-01",
          "Speakers": "Alona Zer",
          "Affiliation": "Institute of Oncology, Rambam Health Campus, Haifa, Israel."
        },
        {
          "Identifier": "677P",
          "Title": "EGFR-BPI: A novel prognostic tool for EGFR-mutated NSCLC with brain metastases",
          "Speakers": "Andreas V. Koulouris",
          "Affiliation": "University of Crete, 70013 Heraklion, Greece."
        },
        {
          "Identifier": "1999P",
          "Title": "Efficacy and safety of SY-5007, a highly selective RET inhibitor in RET fusion-positive NSCLC patients: Primary analysis from phase II study",
          "Speakers": "Anwen Xiong",
          "Affiliation": "Department of Medical Oncology Shanghai Pulmonary Hospital, School of Medicine, Tongji University Shanghai People's Republic of China."
        },
        {
          "Identifier": "915O",
          "Title": "KRAS G12D inhibitor HRS-4642 in patients with KRAS G12D-mutant advanced solid tumors: A phase I trial",
          "Speakers": "Anwen Xiong",
          "Affiliation": "Department of Medical Oncology Shanghai Pulmonary Hospital, School of Medicine, Tongji University Shanghai People's Republic of China."
        },
        {
          "Identifier": "928P",
          "Title": "Safety and activity of the MET-TKI DO-2 in patients with advanced solid tumors: Phase I study",
          "Speakers": "Barend J. Sikkema",
          "Affiliation": "Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, the Netherlands."
        },
        {
          "Identifier": "1852MO",
          "Title": "KEYMAKER-U01 substudy 01A: Investigational agents + pembrolizumab (pembro) and chemotherapy (chemo) in untreated stage IV non-small cell lung cancer (NSCLC)",
          "Speakers": "Charu Aggarwal",
          "Affiliation": "Abramson Cancer Center, University of Pennsylvania, Philadelphia."
        },
        {
          "Identifier": "2771P",
          "Title": "3S-SCLC: Preliminary results of a phase II study of systemic treatments-based split-course adaptive thoracic stereotactic body radiation therapy (3-S) for extensive-stage SCLC",
          "Speakers": "Cheng Chen",
          "Affiliation": "College of Computer Science and Technology, Xinjiang University, Urumqi, China."
        },
        {
          "Identifier": "LBA33",
          "Title": "Circulating Tumor (ct) DNA-Guided Anti-EGFR Rechallenge Strategy in Metastatic Colorectal Cancer (mCRC): Final results of the phase II randomized CITRIC trial",
          "Speakers": "Clara Montagut",
          "Affiliation": "Hospital del Mar Research Institute (IMIM), Barcelona, Spain."
        },
        {
          "Identifier": "2045eP",
          "Title": "Perivascular spaces as immune gatekeepers in brain metastases: A novel marker for prognosis and immune response",
          "Speakers": "Claudia Maletzki",
          "Affiliation": "Department of Medicine, Clinic III - Hematology, Oncology, Rostock University Medical Center, University of Rostock, Germany."
        },
        {
          "Identifier": "1914P",
          "Title": "Sex differences in the tolerability to novel targeted therapies: Insights from a French lung cancer data system",
          "Speakers": "Claudia Parisi",
          "Affiliation": "Department of Cancer Medicine, Thoracic Group and International Center for Thoracic Cancers, Paris-Saclay University, Villejuif, France."
        },
        {
          "Identifier": "1992P",
          "Title": "Targeting KRAS codon 13 mutations using combinations with RMC-8839, a novel RAS(ON) G13C-selective, tri-complex inhibitor, in non-small cell lung cancer",
          "Speakers": "Colin R R. Lindsay",
          "Affiliation": "The University of Manchester, Manchester, United Kingdom."
        },
        {
          "Identifier": "995P",
          "Title": "Food for thought: Effect of a high-fat meal on DO-2, a novel MET-kinase inhibitor",
          "Speakers": "Daan Lanser",
          "Affiliation": "Erasmus University Medical Center, Rotterdam, the Netherlands."
        },
        {
          "Identifier": "882eP",
          "Title": "Phase I study of intratumoural (IT) IVX037, a novel CD55-targeted oncolytic RNA virus, in advanced microsatellite stable (MSS) colorectal cancer (CRC): Serum biomarkers, viral kinetics, and KRAS mutation analysis",
          "Speakers": "Darren Shafren",
          "Affiliation": "School of Biomedical Science and Pharmacy, University of Newcastle, Newcastle, Australia."
        },
        {
          "Identifier": "743P",
          "Title": "Combined analysis of overall survival (OS) from the phase III CodeBreaK 300 and phase Ib CodeBreaK 101 studies of sotorasib 960 mg plus panitumumab (soto960+pani) therapy for chemorefractory KRAS G12C-mutated metastatic colorectal cancer (mCRC)",
          "Speakers": "David S. Hong",
          "Affiliation": "1Department of Investigational Cancer Therapeutics, The University of Texas Anderson Cancer Center, Houston, Texas, USA"
        },
        {
          "Identifier": "914O",
          "Title": "HRS-7058, a KRAS G12C inhibitor (G12Ci), in advanced solid tumors with KRAS G12C mutation: A phase I, multi-center, first-in-human study",
          "Speakers": "Dingzhi Huang",
          "Affiliation": "Tianjin Medical University Cancer Institute & Hospital, Tianjin, China."
        },
        {
          "Identifier": "LBA66",
          "Title": "Ensartinib as adjuvant therapy in patients (pts) with stage IBIIIB ALK-positive (ALK+) non-small cell lung cancer (NSCLC) after complete tumor resection: the phase III randomized ELEVATE trial",
          "Speakers": "Dongsheng Yue",
          "Affiliation": "Department of Lung Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China."
        },
        {
          "Identifier": "671P",
          "Title": "IT-IO: Intrathecal administration of nivolumab and ipilimumab in combination with systemic combination of nivolumab and ipilimumab in patients with non-small cell lung cancer or melanoma and newly diagnosed leptomeningeal metastasis, a multicentric phase I study",
          "Speakers": "Emilie Le Rhun",
          "Affiliation": "Departments of Neurosurgery and Neurology, University Hospital Zurich, Ramistrasse 102, Zurich, Switzerland."
        },
        {
          "Identifier": "1991P",
          "Title": "Overall survival (OS) with sotorasib plus carboplatin and pemetrexed in KRAS G12C-mutated advanced non-small cell lung cancer (NSCLC) from the global phase Ib CodeBreaK 101 study",
          "Speakers": "Enriqueta Felip",
          "Affiliation": "Oncology Department, Vall d'Hebron University Hospital, Barcelona, Spain."
        },
        {
          "Identifier": "LBA76",
          "Title": "Paclitaxel-bevacizumab  atezolizumab in advanced non-squamous NSCLC progressing after chemo-immunotherapy: IFCT-2201 ADAPTABLE randomized phase II trial",
          "Speakers": "Etienne Giroux-Leprieur",
          "Affiliation": ""
        },
        {
          "Identifier": "996P",
          "Title": "Phase II trial of alectinib in ALK-altered solid tumours and NSCLC with negative standard care testing: Australian molecular screening and therapeutics (MoST) substudy 14",
          "Speakers": "Frank P. Lin",
          "Affiliation": "Garvan Institute of Medical Research, Sydney, Australia."
        },
        {
          "Identifier": "",
          "Title": "DLL3-targeted T-cell engagers: a novel approach to treating recurrent ES-SCLC",
          "Speakers": "Giannis Mountzios",
          "Affiliation": "Fourth Department of Medical Oncology and Clinical Trials Unit, Henry Dunant Hospital Center Athens, Greece."
        },
        {
          "Identifier": "2773P",
          "Title": "Patient-reported outcomes (PROs) from DeLLphi-304: The first phase III trial evaluating tarlatamab and chemotherapy (CTx) in patients (Pts) with previously treated small cell lung cancer (SCLC)",
          "Speakers": "Giannis Mountzios",
          "Affiliation": "Fourth Department of Medical Oncology and Clinical Trials Unit, Henry Dunant Hospital Center Athens, Greece."
        },
        {
          "Identifier": "2978P",
          "Title": "Real-world validation of AI-defined lung nodule malignancy score (qXR-LNMS) in predicting risk of lung cancer: Interim results from phase II",
          "Speakers": "Hari Kishan Gonuguntla",
          "Affiliation": "Department of Interventional Pulmonology Yashoda Hospitals Hyderabad India."
        },
        {
          "Identifier": "921MO",
          "Title": "Phase I global study of Iza-Bren (BL-B01D1), an EGFR x HER3 bispecific antibody-drug conjugate (ADC), in patients with metastatic or unresectable non-small cell lung cancer (NSCLC) and other solid tumors",
          "Speakers": "Helena A. Yu",
          "Affiliation": "Department of Medicine, Memorial Sloan Kettering Cancer Center, NY, USA."
        },
        {
          "Identifier": "2758MO",
          "Title": "Updated results from a phase I/II study of gocatamig for small cell lung cancer (SCLC) and other neuroendocrine cancers",
          "Speakers": "Himisha Beltran",
          "Affiliation": "Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA."
        },
        {
          "Identifier": "1823P",
          "Title": "A phase II, two-cohort study of neoadjuvant chemoimmuotherapy  bevacizumab followed by concurrent chemoradiotherapy and consolidative immunotherapy in locally advanced non-small cell lung cancer (GASTO-1086)",
          "Speakers": "Hui Liu",
          "Affiliation": "Department of Basic Public Health, Guangzhou Center for Disease Control and Prevention, Guangzhou 510440, China."
        },
        {
          "Identifier": "1851MO",
          "Title": "Pembrolizumab plus chemotherapy (PEM + CT) versus pembrolizumab (PEM) as first-line therapy for advanced NSCLC with PD-L1 tumor proportion score (TPS) 50%: Open-label, phase III, randomized trial (PAULIEN)",
          "Speakers": "Ilias Houda",
          "Affiliation": "Department of Pulmonary Medicine, Amsterdam UMC, VU Medical Center, Amsterdam, the Netherlands."
        }
      ]
    },
    "table_context": "**BIOMARKER/MOA TABLE:**\n| Biomarker/MOA   |   # Studies | Identifiers                                                                       | Sessions                                                 |\n|:----------------|------------:|:----------------------------------------------------------------------------------|:---------------------------------------------------------|\n| EGFR            |          68 | 1948P, 853P, 677P, 2071eP, 891eP, LBA33, 3029eP, 2064eP, 249eP, , +58 more        | Poster, ePoster, Proffered Paper, +2 more                |\n| BRAF            |          43 | 2996P, 853P, 1682P, 891eP, , 687P, 1646P, , 2991P, 803P, +33 more                 | Poster, ePoster, Industry-Sponsored S, +2 more           |\n| KRAS            |          33 | LBA84, 1016eTiP, 265eP, 1990P, 915O, , 1992P, 3029eP, 882eP, 743P, +23 more       | Proffered Paper, ePoster, Poster, +3 more                |\n| PD-L1           |          25 | 1879P, 1795P, 2021P, 1851MO, 1886P, 1962P, 1869P, 1920P, 255eP, 2025TiP, +15 more | Poster, Mini Oral Session, ePoster, +1 more              |\n| ALK             |          23 | 972P, 1984P, 1828P, 1983P, LBA66, 996P, 1982P, 2567P, , 1979P, +13 more           | Poster, Mini Oral Session, Industry-Sponsored S, +2 more |\n| MET             |          16 | 928P, 2074eP, 995P, 1795P, 1996P, 1967P, 1997P, 2610MO, 1955P, 932P, +6 more      | Poster, ePoster, Mini Oral Session, +1 more              |\n| ctDNA           |          15 | 2783P, 1893P, 1819P, 1957P, LBA70, 2020P, 1913P, LBA32, 190eP, 125P, +5 more      | Poster, Mini Oral Session, Proffered Paper, +1 more      |\n| HER2            |          10 | , 2002P, 2020P, 540P, 2058eP, 2001P, LBA74, 2003P, LBA75, 738P                    | Industry-Sponsored S, Poster, ePoster, +1 more           |\n| PD-1            |           6 | 1853MO, 2021P, 18P, 1898P, 1938P, 1933P                                           | Mini Oral Session, Poster                                |\n| NTRK            |           4 | 2013P, 171P, 687P, 2998P                                                          | Poster                                                   |\n| ROS1            |           4 | 1988P, 1986P, 2027TiP, 1987MO                                                     | Poster, Mini Oral Session                                |\n| DLL3            |           4 | , 2776P, , 2775P                                                                  | Industry-Sponsored S, Poster                             |\n| TIGIT           |           3 | 1853MO, 3061eP, 1885P                                                             | Mini Oral Session, ePoster, Poster                       |\n| RET             |           3 | 1999P, 2000P, 2998P                                                               | Poster                                                   |\n| VEGF            |           3 | 1860P, 792P, 875eP                                                                | Poster, ePoster                                          |\n| HER3            |           2 | 921MO, 933P                                                                       | Mini Oral Session, Poster                                |\n| FGFR            |           2 | 1931P, 1932P                                                                      | Poster                                                   |\n| CTC             |           2 | 190eP, 1813eP                                                                     | ePoster                                                  |\n| FGFR1           |           1 | 2067eP                                                                            | ePoster                                                  |\n| CTLA-4          |           1 | 18P                                                                               | Poster                                                   |\n| LAG-3           |           1 | 1857P                                                                             | Poster                                                   |\n| TMB             |           1 | 1980P                                                                             | Poster                                                   |\n| MSI             |           1 | 886eP                                                                             | ePoster                                                  |\n| dMMR            |           1 | 886eP                                                                             | ePoster                                                  |\n| MSI-H           |           1 | 886eP                                                                             | ePoster                                                  |\n| PARP            |           1 | 157P                                                                              | Poster                                                   |\n| PIK3CA          |           1 | 846P                                                                              | Poster                                                   |\n| NRG1            |           1 | 1993P                                                                             | Poster                                                   |\n| ERBB2           |           1 | 2003P                                                                             | Poster                                                   |\n\n**NOVEL/EARLY-PHASE STUDIES:**\n| Identifier   | Title                                                                                                                                                                                                                                                                  | Speakers                | Affiliation                                                                                                                              |\n|:-------------|:-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|:------------------------|:-----------------------------------------------------------------------------------------------------------------------------------------|\n| 1016eTiP     | A first-in-human phase I study of LY4066434, a potent and orally bioavailable pan-KRAS inhibitor, in KRAS-mutant solid tumors (Trial in Progress)                                                                                                                      | Shigehisa Kitano        | Department of Advanced Medical Development, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.      |\n| 2023P        | Phase Ib study of valemetostat in combination with datopotamab deruxtecan (Dato-DXd) in advanced non-squamous non-small cell lung cancer (NSCLC): Initial safety results                                                                                               | Alexander I. Spira      | Virginia Cancer Specialists, Fairfax, VA, USA.                                                                                           |\n| 853P         | Landscape of anti-EGFR resistance mutations in RAS/BRAF-wild type left-sided metastatic colorectal cancer: First sequencing results of the phase III CRC01 prospective trial                                                                                           | Alexandra Lebedeva      | Institute for Personalized Oncology, Sechenov First Moscow State Medical University, Moscow 119048, Russia.                              |\n| 1947P        | Phase II study of sacituzumab govitecan (SG), domvanalimab (dom), and zimberelimab (zim) in metastatic non-small cell lung cancer (mNSCLC): VELOCITY-Lung substudy-01                                                                                                  | Alona Zer               | Institute of Oncology, Rambam Health Campus, Haifa, Israel.                                                                              |\n| 677P         | EGFR-BPI: A novel prognostic tool for EGFR-mutated NSCLC with brain metastases                                                                                                                                                                                         | Andreas V. Koulouris    | University of Crete, 70013 Heraklion, Greece.                                                                                            |\n| 1999P        | Efficacy and safety of SY-5007, a highly selective RET inhibitor in RET fusion-positive NSCLC patients: Primary analysis from phase II study                                                                                                                           | Anwen Xiong             | Department of Medical Oncology Shanghai Pulmonary Hospital, School of Medicine, Tongji University Shanghai People's Republic of China.   |\n| 915O         | KRAS G12D inhibitor HRS-4642 in patients with KRAS G12D-mutant advanced solid tumors: A phase I trial                                                                                                                                                                  | Anwen Xiong             | Department of Medical Oncology Shanghai Pulmonary Hospital, School of Medicine, Tongji University Shanghai People's Republic of China.   |\n| 928P         | Safety and activity of the MET-TKI DO-2 in patients with advanced solid tumors: Phase I study                                                                                                                                                                          | Barend J. Sikkema       | Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, the Netherlands.              |\n| 1852MO       | KEYMAKER-U01 substudy 01A: Investigational agents + pembrolizumab (pembro) and chemotherapy (chemo) in untreated stage IV non-small cell lung cancer (NSCLC)                                                                                                           | Charu Aggarwal          | Abramson Cancer Center, University of Pennsylvania, Philadelphia.                                                                        |\n| 2771P        | 3S-SCLC: Preliminary results of a phase II study of systemic treatments-based split-course adaptive thoracic stereotactic body radiation therapy (3-S) for extensive-stage SCLC                                                                                        | Cheng Chen              | College of Computer Science and Technology, Xinjiang University, Urumqi, China.                                                          |\n| LBA33        | Circulating Tumor (ct) DNA-Guided Anti-EGFR Rechallenge Strategy in Metastatic Colorectal Cancer (mCRC): Final results of the phase II randomized CITRIC trial                                                                                                         | Clara Montagut          | Hospital del Mar Research Institute (IMIM), Barcelona, Spain.                                                                            |\n| 2045eP       | Perivascular spaces as immune gatekeepers in brain metastases: A novel marker for prognosis and immune response                                                                                                                                                        | Claudia Maletzki        | Department of Medicine, Clinic III - Hematology, Oncology, Rostock University Medical Center, University of Rostock, Germany.            |\n| 1914P        | Sex differences in the tolerability to novel targeted therapies: Insights from a French lung cancer data system                                                                                                                                                        | Claudia Parisi          | Department of Cancer Medicine, Thoracic Group and International Center for Thoracic Cancers, Paris-Saclay University, Villejuif, France. |\n| 1992P        | Targeting KRAS codon 13 mutations using combinations with RMC-8839, a novel RAS(ON) G13C-selective, tri-complex inhibitor, in non-small cell lung cancer                                                                                                               | Colin R R. Lindsay      | The University of Manchester, Manchester, United Kingdom.                                                                                |\n| 995P         | Food for thought: Effect of a high-fat meal on DO-2, a novel MET-kinase inhibitor                                                                                                                                                                                      | Daan Lanser             | Erasmus University Medical Center, Rotterdam, the Netherlands.                                                                           |\n| 882eP        | Phase I study of intratumoural (IT) IVX037, a novel CD55-targeted oncolytic RNA virus, in advanced microsatellite stable (MSS) colorectal cancer (CRC): Serum biomarkers, viral kinetics, and KRAS mutation analysis                                                   | Darren Shafren          | School of Biomedical Science and Pharmacy, University of Newcastle, Newcastle, Australia.                                                |\n| 743P         | Combined analysis of overall survival (OS) from the phase III CodeBreaK 300 and phase Ib CodeBreaK 101 studies of sotorasib 960 mg plus panitumumab (soto960+pani) therapy for chemorefractory KRAS G12C-mutated metastatic colorectal cancer (mCRC)                   | David S. Hong           | 1Department of Investigational Cancer Therapeutics, The University of Texas Anderson Cancer Center, Houston, Texas, USA                  |\n| 914O         | HRS-7058, a KRAS G12C inhibitor (G12Ci), in advanced solid tumors with KRAS G12C mutation: A phase I, multi-center, first-in-human study                                                                                                                               | Dingzhi Huang           | Tianjin Medical University Cancer Institute & Hospital, Tianjin, China.                                                                  |\n| LBA66        | Ensartinib as adjuvant therapy in patients (pts) with stage IBIIIB ALK-positive (ALK+) non-small cell lung cancer (NSCLC) after complete tumor resection: the phase III randomized ELEVATE trial                                                                       | Dongsheng Yue           | Department of Lung Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.                                     |\n| 671P         | IT-IO: Intrathecal administration of nivolumab and ipilimumab in combination with systemic combination of nivolumab and ipilimumab in patients with non-small cell lung cancer or melanoma and newly diagnosed leptomeningeal metastasis, a multicentric phase I study | Emilie Le Rhun          | Departments of Neurosurgery and Neurology, University Hospital Zurich, Ramistrasse 102, Zurich, Switzerland.                             |\n| 1991P        | Overall survival (OS) with sotorasib plus carboplatin and pemetrexed in KRAS G12C-mutated advanced non-small cell lung cancer (NSCLC) from the global phase Ib CodeBreaK 101 study                                                                                     | Enriqueta Felip         | Oncology Department, Vall d'Hebron University Hospital, Barcelona, Spain.                                                                |\n| LBA76        | Paclitaxel-bevacizumab  atezolizumab in advanced non-squamous NSCLC progressing after chemo-immunotherapy: IFCT-2201 ADAPTABLE randomized phase II trial                                                                                                               | Etienne Giroux-Leprieur |                                                                                                                                          |\n| 996P         | Phase II trial of alectinib in ALK-altered solid tumours and NSCLC with negative standard care testing: Australian molecular screening and therapeutics (MoST) substudy 14                                                                                             | Frank P. Lin            | Garvan Institute of Medical Research, Sydney, Australia.                                                                                 |\n|              | DLL3-targeted T-cell engagers: a novel approach to treating recurrent ES-SCLC                                                                                                                                                                                          | Giannis Mountzios       | Fourth Department of Medical Oncology and Clinical Trials Unit, Henry Dunant Hospital Center Athens, Greece.                             |\n| 2773P        | Patient-reported outcomes (PROs) from DeLLphi-304: The first phase III trial evaluating tarlatamab and chemotherapy (CTx) in patients (Pts) with previously treated small cell lung cancer (SCLC)                                                                      | Giannis Mountzios       | Fourth Department of Medical Oncology and Clinical Trials Unit, Henry Dunant Hospital Center Athens, Greece.                             |\n| 2978P        | Real-world validation of AI-defined lung nodule malignancy score (qXR-LNMS) in predicting risk of lung cancer: Interim results from phase II                                                                                                                           | Hari Kishan Gonuguntla  | Department of Interventional Pulmonology Yashoda Hospitals Hyderabad India.                                                              |\n| 921MO        | Phase I global study of Iza-Bren (BL-B01D1), an EGFR x HER3 bispecific antibody-drug conjugate (ADC), in patients with metastatic or unresectable non-small cell lung cancer (NSCLC) and other solid tumors                                                            | Helena A. Yu            | Department of Medicine, Memorial Sloan Kettering Cancer Center, NY, USA.                                                                 |\n| 2758MO       | Updated results from a phase I/II study of gocatamig for small cell lung cancer (SCLC) and other neuroendocrine cancers                                                                                                                                                | Himisha Beltran         | Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.                                        |\n| 1823P        | A phase II, two-cohort study of neoadjuvant chemoimmuotherapy  bevacizumab followed by concurrent chemoradiotherapy and consolidative immunotherapy in locally advanced non-small cell lung cancer (GASTO-1086)                                                        | Hui Liu                 | Department of Basic Public Health, Guangzhou Center for Disease Control and Prevention, Guangzhou 510440, China.                         |\n| 1851MO       | Pembrolizumab plus chemotherapy (PEM + CT) versus pembrolizumab (PEM) as first-line therapy for advanced NSCLC with PD-L1 tumor proportion score (TPS) 50%: Open-label, phase III, randomized trial (PAULIEN)                                                          | Ilias Houda             | Department of Pulmonary Medicine, Amsterdam UMC, VU Medical Center, Amsterdam, the Netherlands.                                          |\n"
  },
  "colorectal_cancer": {
    "regimen_groups": [
      {
        "regimen": "Bevacizumab",
        "count": 13,
        "examples": [
          "746P",
          "890eP",
          "792P",
          "731MO",
          "156P"
        ]
      },
      {
        "regimen": "FOLFOX",
        "count": 10,
        "examples": [
          "752P",
          "841P",
          "727MO",
          "751P",
          "746P"
        ]
      },
      {
        "regimen": "Cetuximab",
        "count": 7,
        "examples": [
          "751P",
          "866eP",
          "880eP",
          "835P",
          "809P"
        ]
      },
      {
        "regimen": "Panitumumab",
        "count": 5,
        "examples": [
          "743P",
          "727MO",
          "LBA32",
          "859P",
          "826P"
        ]
      }
    ],
    "unmet_need_signals": [
      {
        "category": "Post-progression",
        "count": 10
      },
      {
        "category": "Sequencing strategies",
        "count": 8
      },
      {
        "category": "Resistance mechanisms",
        "count": 4
      },
      {
        "category": "Elderly patients",
        "count": 2
      },
      {
        "category": "Rare mutations",
        "count": 1
      }
    ],
    "biomarker_moa": {
      "columns": [
        "Biomarker/MOA",
        "# Studies",
        "Identifiers",
        "Sessions"
      ],
      "rows": [
        {
          "Biomarker/MOA": "BRAF",
          "# Studies": 18,
          "Identifiers": "853P, 891eP, 803P, 727MO, 751P, 866eP, LBA32, 880eP, 814P, 728MO, +8 more",
          "Sessions": "Poster, ePoster, Mini Oral Session, +1 more"
        },
        {
          "Biomarker/MOA": "ctDNA",
          "# Studies": 15,
          "Identifiers": "801P, 732MO, LBA9, 771P, LBA32, 750P, 1772eP, 822P, 768P, 770P, +5 more",
          "Sessions": "Poster, Mini Oral Session, Proffered Paper, +1 more"
        },
        {
          "Biomarker/MOA": "MSI",
          "# Studies": 14,
          "Identifiers": "858P, 1756eP, 801P, 802P, , 872eP, 828P, 883eP, 812P, 879eP, +4 more",
          "Sessions": "Poster, ePoster, Industry-Sponsored S, +1 more"
        },
        {
          "Biomarker/MOA": "dMMR",
          "# Studies": 10,
          "Identifiers": "752P, , 872eP, 724O, 742P, 812P, 879eP, LBA29, 772P, 886eP",
          "Sessions": "Poster, Industry-Sponsored S, ePoster, +1 more"
        },
        {
          "Biomarker/MOA": "EGFR",
          "# Studies": 10,
          "Identifiers": "853P, 891eP, LBA33, 2959eP, 817P, 792P, 728MO, 875eP, 738P, 846P",
          "Sessions": "Poster, ePoster, Proffered Paper, +1 more"
        },
        {
          "Biomarker/MOA": "MSI-H",
          "# Studies": 6,
          "Identifiers": "802P, , 872eP, LBA29, 772P, 886eP",
          "Sessions": "Poster, Industry-Sponsored S, ePoster, +1 more"
        },
        {
          "Biomarker/MOA": "HER2",
          "# Studies": 5,
          "Identifiers": "806P, 737MO, 746P, 808P, 738P",
          "Sessions": "Poster, Mini Oral Session"
        },
        {
          "Biomarker/MOA": "PD-1",
          "# Studies": 4,
          "Identifiers": "802P, 905eTiP, 906eTiP, 796P",
          "Sessions": "Poster, ePoster"
        },
        {
          "Biomarker/MOA": "KRAS",
          "# Studies": 4,
          "Identifiers": "882eP, 743P, , 859P",
          "Sessions": "ePoster, Poster, Industry-Sponsored S"
        },
        {
          "Biomarker/MOA": "VEGF",
          "# Studies": 3,
          "Identifiers": "792P, 875eP, 796P",
          "Sessions": "Poster, ePoster"
        },
        {
          "Biomarker/MOA": "PD-L1",
          "# Studies": 2,
          "Identifiers": "752P, 779P",
          "Sessions": "Poster"
        },
        {
          "Biomarker/MOA": "PIK3CA",
          "# Studies": 2,
          "Identifiers": "735P, 846P",
          "Sessions": "Poster"
        },
        {
          "Biomarker/MOA": "CEACAM5",
          "# Studies": 1,
          "Identifiers": "962P",
          "Sessions": "Poster"
        }
      ]
    },
    "novel_studies": {
      "columns": [
        "Identifier",
        "Title",
        "Speakers",
        "Affiliation"
      ],
      "rows": [
        {
          "Identifier": "775P",
          "Title": "Sequencing neoadjuvant chemotherapy and short course radiation therapy in locally advanced rectal cancer: A phase II randomized controlled trial [SPADE study]",
          "Speakers": "Abhishek Shinghal",
          "Affiliation": "Department of Radiation Oncology, Mahamana Pandit Madan Mohan Malaviya Cancer Centre and Homi Bhabha Cancer Hospital, Tata Memorial Centre, Homi Bhabha National Institute, Varanasi, India."
        },
        {
          "Identifier": "853P",
          "Title": "Landscape of anti-EGFR resistance mutations in RAS/BRAF-wild type left-sided metastatic colorectal cancer: First sequencing results of the phase III CRC01 prospective trial",
          "Speakers": "Alexandra Lebedeva",
          "Affiliation": "Institute for Personalized Oncology, Sechenov First Moscow State Medical University, Moscow 119048, Russia."
        },
        {
          "Identifier": "1018eTiP",
          "Title": "A phase I trial of RGT-61159, an oral MYB transcription factor inhibitor, for patients with relapsed/refractory (R/R) adenoid cystic carcinoma (ACC) and colorectal cancer (CRC)",
          "Speakers": "Renata Ferrarotto",
          "Affiliation": "The University of Texas Anderson Cancer Center, Houston, Texas, USA."
        },
        {
          "Identifier": "781P",
          "Title": "Prognostic factors in locally advanced rectal cancer (LARC) in the ISANOX Trial: Report from a phase II trial",
          "Speakers": "Amina Mokrani",
          "Affiliation": ""
        },
        {
          "Identifier": "780P",
          "Title": "Updated results of the ISANOX phase II trial: Neoadjuvant chemotherapy with FOLFIRINOX and short-course radiotherapy in locally advanced rectal cancer",
          "Speakers": "Amina Mokrani",
          "Affiliation": ""
        },
        {
          "Identifier": "878eP",
          "Title": "Prioritising colonoscopy: Impact of a novel liquid biopsy blood test on PROMs and PREMs in surveillance colonoscopy using a value-based approach",
          "Speakers": "Chris Stewart",
          "Affiliation": "CLL Society, CA."
        },
        {
          "Identifier": "881eP",
          "Title": "Long-term neoadjuvant chemoradiotherapy (nCRT) combined with camrelizumab for locally advanced rectal cancer: A single-arm, prospective, phase II clinical study",
          "Speakers": "Chung B. Zhao",
          "Affiliation": "University of Western Australia, Western Australia 6009, Australia."
        },
        {
          "Identifier": "LBA33",
          "Title": "Circulating Tumor (ct) DNA-Guided Anti-EGFR Rechallenge Strategy in Metastatic Colorectal Cancer (mCRC): Final results of the phase II randomized CITRIC trial",
          "Speakers": "Clara Montagut",
          "Affiliation": "Hospital del Mar Research Institute (IMIM), Barcelona, Spain."
        },
        {
          "Identifier": "882eP",
          "Title": "Phase I study of intratumoural (IT) IVX037, a novel CD55-targeted oncolytic RNA virus, in advanced microsatellite stable (MSS) colorectal cancer (CRC): Serum biomarkers, viral kinetics, and KRAS mutation analysis",
          "Speakers": "Darren Shafren",
          "Affiliation": "School of Biomedical Science and Pharmacy, University of Newcastle, Newcastle, Australia."
        },
        {
          "Identifier": "743P",
          "Title": "Combined analysis of overall survival (OS) from the phase III CodeBreaK 300 and phase Ib CodeBreaK 101 studies of sotorasib 960 mg plus panitumumab (soto960+pani) therapy for chemorefractory KRAS G12C-mutated metastatic colorectal cancer (mCRC)",
          "Speakers": "David S. Hong",
          "Affiliation": "1Department of Investigational Cancer Therapeutics, The University of Texas Anderson Cancer Center, Houston, Texas, USA"
        },
        {
          "Identifier": "838P",
          "Title": "Phase I/II dose-escalation study evaluating ginisortamab (UCB6114), an anti-gremlin-1 monoclonal antibody (mAb) with first-in-class potential, in combination with trifluridine/tipiracil (TFD/TPI) in advanced solid tumours",
          "Speakers": "Debashis Sarker",
          "Affiliation": "Department of Research Oncology, Guys Hospital, Kings College London, SE1 9RT London, UK."
        },
        {
          "Identifier": "747P",
          "Title": "Regorafenib plus Irinotecan versus regorafenib alone in metastatic colorectal cancer after standard therapies failure in cyclin D1 A/A(870) genotype patients: The randomised phase III NEXT-REGIRI trial",
          "Speakers": "Emmanuelle Samalin-Scalzi",
          "Affiliation": "Institut Régional du Cancer de Montpellier, Montpellier, France."
        },
        {
          "Identifier": "1597eTiP",
          "Title": "NEOGAP-CRC-01: A first-in-human phase I/IIa trial of personalised tumour trained lymphocytes (pTTL) in stage IV colorectal cancer",
          "Speakers": "Maximilian Kordes",
          "Affiliation": "Division of Biomolecular and Cellular Medicine, Karolinska Institutet, ANA Futura, Huddinge, Stockholm, Sweden."
        },
        {
          "Identifier": "802P",
          "Title": "Nous-209 immunotherapy with pembrolizumab for microsatellite instability high (MSI-H) metastatic colorectal cancer, refractory to anti-PD-1: Phase II trial results",
          "Speakers": "Francisco Javier Ros Montana",
          "Affiliation": "Vall D'Hebron University Hospital (HUVH) and Vall D'Hebron Institute of Oncology (VHIO), Barcelona, Spain."
        },
        {
          "Identifier": "841P",
          "Title": "Phase I/II dose-escalation study evaluating ginisortamab (UCB6114), an anti-gremlin-1 monoclonal antibody (mAb) with first-in-class potential, in combination with 5-fluorouracil, leucovorin and oxaliplatin (mFOLFOX6) in advanced solid tumours",
          "Speakers": "Heinz Josef Lenz",
          "Affiliation": "Division of Medical Oncology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, CA, USA."
        },
        {
          "Identifier": "727MO",
          "Title": "FOLFOX plus PANITUMUMAB (Pmab) according to a stop-and-go strategy in first-line in patients (pts) with non-mutated RAS/BRAF metastatic colorectal cancer (mCRC): Results of the FFCD 1605  OPTIPRIME phase II trial",
          "Speakers": "Jean-Baptiste Bachet",
          "Affiliation": "Sorbonne University, Department of Hepato-Gastroenterology, Pitié-Salpêtrière Hospital, Paris, France."
        },
        {
          "Identifier": "751P",
          "Title": "Subsequent therapies in the phase III BREAKWATER study of first-line encorafenib + cetuximab + mFOLFOX6 in patients with BRAF V600E-mutant metastatic colorectal cancer",
          "Speakers": "Josep Tabernero",
          "Affiliation": "Vall d'Hebron Hospital Campus and Institute of Oncology (VHIO), UVic-UCC, IOB-Quirón, Barcelona, Spain."
        },
        {
          "Identifier": "737MO",
          "Title": "Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-positive (HER2+) metastatic colorectal cancer (mCRC): Final analysis of DESTINY-CRC02, a randomized, phase II trial",
          "Speakers": "Kanwal Raghav",
          "Affiliation": "Department of Gastrointestinal Medical Oncology, The University of Texas Anderson Cancer Center, Houston, TX."
        },
        {
          "Identifier": "823P",
          "Title": "A phase II study of mFOLFOXIRI following metastasectomy in oligometastatic colorectal cancer: (FANTASTIC)",
          "Speakers": "Kozo Kataoka",
          "Affiliation": "Division of Lower G.I., Department of Gastroenterological Surgery, School of Medicine, Hyogo Medical University, Nishinomiya 663-8501, Japan."
        },
        {
          "Identifier": "866eP",
          "Title": "A phase II, open-label study of toripalimab, cetuximab plus FOLFIRI as first-line treatment of unresectable left-sided RAS/BRAF wild-type metastatic colorectal cancer (Tesla study)",
          "Speakers": "Liangjun Zhu",
          "Affiliation": "Department of Radiotherapy, The Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing, China."
        },
        {
          "Identifier": "773P",
          "Title": "Integration of cadonilimab into total neoadjuvant therapy for pMMR/MSS locally advanced rectal cancer: Phase II efficacy and safety outcomes",
          "Speakers": "Lingling Feng",
          "Affiliation": "Department of Surgery, NY 10065, USA, Key Laboratory of Pesticide and Chemical Biology (CCNU), Ministry of Education, College of Chemistry, Central China Normal University, Wuhan, Hubei 430079, China."
        },
        {
          "Identifier": "851P",
          "Title": "A phase I trial of botensilimab, balstilimab and regorafenib (BBR) in chemotherapy-resistant patients with microsatellite stable (MSS) metastatic colorectal cancer",
          "Speakers": "Marwan Fakih",
          "Affiliation": "Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, CA"
        },
        {
          "Identifier": "731MO",
          "Title": "Telisotuzumab adizutecan (ABBV-400; Temab-A) in combination with bevacizumab (Bev) vs standard of care (SOC) in patients (pts) with 3L+ colorectal cancer (CRC): Dose expansion results of a phase I study",
          "Speakers": "Michael Cecchini",
          "Affiliation": "Yale New Haven Hospital, CT, USA."
        },
        {
          "Identifier": "799P",
          "Title": "Fruquintinib plus tislelizumab in microsatellite stable metastatic colorectal cancer: Results from a phase Ib/II study",
          "Speakers": "N. Arvind Dasari",
          "Affiliation": "Anderson Cancer Center, Houston, TX."
        },
        {
          "Identifier": "1009eP",
          "Title": "First-in-human study of acoustic cluster therapy consisting of PS101 combined with chemotherapy and insonation in patients with liver metastases of colorectal cancer origin",
          "Speakers": "Nina Tunariu",
          "Affiliation": "The Institute of Cancer Research and the Royal Marsden Hospital, Sutton, Surrey, London"
        },
        {
          "Identifier": "822P",
          "Title": "Evaluating ctDNA as a predictive biomarker in a phase I clinical trial of mosperafenib in BRAFV600E-mutant colorectal cancer",
          "Speakers": "Oliver E. Bechter",
          "Affiliation": "Department of General Medical Oncology, University Hospitals Leuven, KU Leuven, Belgium."
        },
        {
          "Identifier": "812P",
          "Title": "Efficacy and safety of two schemes of nivolumab (Nivo) and ipilimumab (Ipi) in MSI/dMMR metastatic colorectal cancer (mCRC): The PRODIGE-74 GERCOR NIPISAFE randomized non-comparative phase II trial",
          "Speakers": "Romain Cohen",
          "Affiliation": "Sorbonne University and Department of Medical Oncology, Saint-Antoine Hospital, Paris 75015, France."
        },
        {
          "Identifier": "879eP",
          "Title": "Nivolumab and ipilimumab in anti-PD1-resistant MSI/dMMR metastatic colorectal cancer: Interim analysis of the GERCOR NIPIRESCUE phase II trial",
          "Speakers": "Romain Cohen",
          "Affiliation": "Sorbonne University and Department of Medical Oncology, Saint-Antoine Hospital, Paris 75015, France."
        },
        {
          "Identifier": "831P",
          "Title": "Cadonilimab combined with FOLFOXIRI and bevacizumab as first-line treatment for microsatellite stable/proficient mismatch repair (MSS/pMMR) metastatic colorectal cancer (mCRC): Update result from a multicenter, phase II study (SYLT-026)",
          "Speakers": "Rongbo Lin",
          "Affiliation": "Department of Medical Oncology, Fujian Medical University Cancer Hospital and Fujian Cancer Hospital, Fuzhou, Fujian, People's Republic of China."
        },
        {
          "Identifier": "778P",
          "Title": "Prognostic significance of tumor deposits in locally advanced rectal cancer: Post-hoc analysis of a phase III trial",
          "Speakers": "RunKai Cai",
          "Affiliation": "Department of Medical Oncology, Department of General Surgery, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou 510655, China"
        }
      ]
    },
    "table_context": "**BIOMARKER/MOA TABLE:**\n| Biomarker/MOA   |   # Studies | Identifiers                                                               | Sessions                                            |\n|:----------------|------------:|:--------------------------------------------------------------------------|:----------------------------------------------------|\n| BRAF            |          18 | 853P, 891eP, 803P, 727MO, 751P, 866eP, LBA32, 880eP, 814P, 728MO, +8 more | Poster, ePoster, Mini Oral Session, +1 more         |\n| ctDNA           |          15 | 801P, 732MO, LBA9, 771P, LBA32, 750P, 1772eP, 822P, 768P, 770P, +5 more   | Poster, Mini Oral Session, Proffered Paper, +1 more |\n| MSI             |          14 | 858P, 1756eP, 801P, 802P, , 872eP, 828P, 883eP, 812P, 879eP, +4 more      | Poster, ePoster, Industry-Sponsored S, +1 more      |\n| dMMR            |          10 | 752P, , 872eP, 724O, 742P, 812P, 879eP, LBA29, 772P, 886eP                | Poster, Industry-Sponsored S, ePoster, +1 more      |\n| EGFR            |          10 | 853P, 891eP, LBA33, 2959eP, 817P, 792P, 728MO, 875eP, 738P, 846P          | Poster, ePoster, Proffered Paper, +1 more           |\n| MSI-H           |           6 | 802P, , 872eP, LBA29, 772P, 886eP                                         | Poster, Industry-Sponsored S, ePoster, +1 more      |\n| HER2            |           5 | 806P, 737MO, 746P, 808P, 738P                                             | Poster, Mini Oral Session                           |\n| PD-1            |           4 | 802P, 905eTiP, 906eTiP, 796P                                              | Poster, ePoster                                     |\n| KRAS            |           4 | 882eP, 743P, , 859P                                                       | ePoster, Poster, Industry-Sponsored S               |\n| VEGF            |           3 | 792P, 875eP, 796P                                                         | Poster, ePoster                                     |\n| PD-L1           |           2 | 752P, 779P                                                                | Poster                                              |\n| PIK3CA          |           2 | 735P, 846P                                                                | Poster                                              |\n| CEACAM5         |           1 | 962P                                                                      | Poster                                              |\n\n**NOVEL/EARLY-PHASE STUDIES:**\n| Identifier   | Title                                                                                                                                                                                                                                                | Speakers                     | Affiliation                                                                                                                                                                                              |\n|:-------------|:-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|:-----------------------------|:---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n| 775P         | Sequencing neoadjuvant chemotherapy and short course radiation therapy in locally advanced rectal cancer: A phase II randomized controlled trial [SPADE study]                                                                                       | Abhishek Shinghal            | Department of Radiation Oncology, Mahamana Pandit Madan Mohan Malaviya Cancer Centre and Homi Bhabha Cancer Hospital, Tata Memorial Centre, Homi Bhabha National Institute, Varanasi, India.             |\n| 853P         | Landscape of anti-EGFR resistance mutations in RAS/BRAF-wild type left-sided metastatic colorectal cancer: First sequencing results of the phase III CRC01 prospective trial                                                                         | Alexandra Lebedeva           | Institute for Personalized Oncology, Sechenov First Moscow State Medical University, Moscow 119048, Russia.                                                                                              |\n| 1018eTiP     | A phase I trial of RGT-61159, an oral MYB transcription factor inhibitor, for patients with relapsed/refractory (R/R) adenoid cystic carcinoma (ACC) and colorectal cancer (CRC)                                                                     | Renata Ferrarotto            | The University of Texas Anderson Cancer Center, Houston, Texas, USA.                                                                                                                                     |\n| 781P         | Prognostic factors in locally advanced rectal cancer (LARC) in the ISANOX Trial: Report from a phase II trial                                                                                                                                        | Amina Mokrani                |                                                                                                                                                                                                          |\n| 780P         | Updated results of the ISANOX phase II trial: Neoadjuvant chemotherapy with FOLFIRINOX and short-course radiotherapy in locally advanced rectal cancer                                                                                               | Amina Mokrani                |                                                                                                                                                                                                          |\n| 878eP        | Prioritising colonoscopy: Impact of a novel liquid biopsy blood test on PROMs and PREMs in surveillance colonoscopy using a value-based approach                                                                                                     | Chris Stewart                | CLL Society, CA.                                                                                                                                                                                         |\n| 881eP        | Long-term neoadjuvant chemoradiotherapy (nCRT) combined with camrelizumab for locally advanced rectal cancer: A single-arm, prospective, phase II clinical study                                                                                     | Chung B. Zhao                | University of Western Australia, Western Australia 6009, Australia.                                                                                                                                      |\n| LBA33        | Circulating Tumor (ct) DNA-Guided Anti-EGFR Rechallenge Strategy in Metastatic Colorectal Cancer (mCRC): Final results of the phase II randomized CITRIC trial                                                                                       | Clara Montagut               | Hospital del Mar Research Institute (IMIM), Barcelona, Spain.                                                                                                                                            |\n| 882eP        | Phase I study of intratumoural (IT) IVX037, a novel CD55-targeted oncolytic RNA virus, in advanced microsatellite stable (MSS) colorectal cancer (CRC): Serum biomarkers, viral kinetics, and KRAS mutation analysis                                 | Darren Shafren               | School of Biomedical Science and Pharmacy, University of Newcastle, Newcastle, Australia.                                                                                                                |\n| 743P         | Combined analysis of overall survival (OS) from the phase III CodeBreaK 300 and phase Ib CodeBreaK 101 studies of sotorasib 960 mg plus panitumumab (soto960+pani) therapy for chemorefractory KRAS G12C-mutated metastatic colorectal cancer (mCRC) | David S. Hong                | 1Department of Investigational Cancer Therapeutics, The University of Texas Anderson Cancer Center, Houston, Texas, USA                                                                                  |\n| 838P         | Phase I/II dose-escalation study evaluating ginisortamab (UCB6114), an anti-gremlin-1 monoclonal antibody (mAb) with first-in-class potential, in combination with trifluridine/tipiracil (TFD/TPI) in advanced solid tumours                        | Debashis Sarker              | Department of Research Oncology, Guys Hospital, Kings College London, SE1 9RT London, UK.                                                                                                                |\n| 747P         | Regorafenib plus Irinotecan versus regorafenib alone in metastatic colorectal cancer after standard therapies failure in cyclin D1 A/A(870) genotype patients: The randomised phase III NEXT-REGIRI trial                                            | Emmanuelle Samalin-Scalzi    | Institut Régional du Cancer de Montpellier, Montpellier, France.                                                                                                                                         |\n| 1597eTiP     | NEOGAP-CRC-01: A first-in-human phase I/IIa trial of personalised tumour trained lymphocytes (pTTL) in stage IV colorectal cancer                                                                                                                    | Maximilian Kordes            | Division of Biomolecular and Cellular Medicine, Karolinska Institutet, ANA Futura, Huddinge, Stockholm, Sweden.                                                                                          |\n| 802P         | Nous-209 immunotherapy with pembrolizumab for microsatellite instability high (MSI-H) metastatic colorectal cancer, refractory to anti-PD-1: Phase II trial results                                                                                  | Francisco Javier Ros Montana | Vall D'Hebron University Hospital (HUVH) and Vall D'Hebron Institute of Oncology (VHIO), Barcelona, Spain.                                                                                               |\n| 841P         | Phase I/II dose-escalation study evaluating ginisortamab (UCB6114), an anti-gremlin-1 monoclonal antibody (mAb) with first-in-class potential, in combination with 5-fluorouracil, leucovorin and oxaliplatin (mFOLFOX6) in advanced solid tumours   | Heinz Josef Lenz             | Division of Medical Oncology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, CA, USA.                                                                   |\n| 727MO        | FOLFOX plus PANITUMUMAB (Pmab) according to a stop-and-go strategy in first-line in patients (pts) with non-mutated RAS/BRAF metastatic colorectal cancer (mCRC): Results of the FFCD 1605  OPTIPRIME phase II trial                                 | Jean-Baptiste Bachet         | Sorbonne University, Department of Hepato-Gastroenterology, Pitié-Salpêtrière Hospital, Paris, France.                                                                                                   |\n| 751P         | Subsequent therapies in the phase III BREAKWATER study of first-line encorafenib + cetuximab + mFOLFOX6 in patients with BRAF V600E-mutant metastatic colorectal cancer                                                                              | Josep Tabernero              | Vall d'Hebron Hospital Campus and Institute of Oncology (VHIO), UVic-UCC, IOB-Quirón, Barcelona, Spain.                                                                                                  |\n| 737MO        | Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-positive (HER2+) metastatic colorectal cancer (mCRC): Final analysis of DESTINY-CRC02, a randomized, phase II trial                                                                       | Kanwal Raghav                | Department of Gastrointestinal Medical Oncology, The University of Texas Anderson Cancer Center, Houston, TX.                                                                                            |\n| 823P         | A phase II study of mFOLFOXIRI following metastasectomy in oligometastatic colorectal cancer: (FANTASTIC)                                                                                                                                            | Kozo Kataoka                 | Division of Lower G.I., Department of Gastroenterological Surgery, School of Medicine, Hyogo Medical University, Nishinomiya 663-8501, Japan.                                                            |\n| 866eP        | A phase II, open-label study of toripalimab, cetuximab plus FOLFIRI as first-line treatment of unresectable left-sided RAS/BRAF wild-type metastatic colorectal cancer (Tesla study)                                                                 | Liangjun Zhu                 | Department of Radiotherapy, The Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing, China.                                 |\n| 773P         | Integration of cadonilimab into total neoadjuvant therapy for pMMR/MSS locally advanced rectal cancer: Phase II efficacy and safety outcomes                                                                                                         | Lingling Feng                | Department of Surgery, NY 10065, USA, Key Laboratory of Pesticide and Chemical Biology (CCNU), Ministry of Education, College of Chemistry, Central China Normal University, Wuhan, Hubei 430079, China. |\n| 851P         | A phase I trial of botensilimab, balstilimab and regorafenib (BBR) in chemotherapy-resistant patients with microsatellite stable (MSS) metastatic colorectal cancer                                                                                  | Marwan Fakih                 | Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, CA                                                                                           |\n| 731MO        | Telisotuzumab adizutecan (ABBV-400; Temab-A) in combination with bevacizumab (Bev) vs standard of care (SOC) in patients (pts) with 3L+ colorectal cancer (CRC): Dose expansion results of a phase I study                                           | Michael Cecchini             | Yale New Haven Hospital, CT, USA.                                                                                                                                                                        |\n| 799P         | Fruquintinib plus tislelizumab in microsatellite stable metastatic colorectal cancer: Results from a phase Ib/II study                                                                                                                               | N. Arvind Dasari             | Anderson Cancer Center, Houston, TX.                                                                                                                                                                     |\n| 1009eP       | First-in-human study of acoustic cluster therapy consisting of PS101 combined with chemotherapy and insonation in patients with liver metastases of colorectal cancer origin                                                                         | Nina Tunariu                 | The Institute of Cancer Research and the Royal Marsden Hospital, Sutton, Surrey, London                                                                                                                  |\n| 822P         | Evaluating ctDNA as a predictive biomarker in a phase I clinical trial of mosperafenib in BRAFV600E-mutant colorectal cancer                                                                                                                         | Oliver E. Bechter            | Department of General Medical Oncology, University Hospitals Leuven, KU Leuven, Belgium.                                                                                                                 |\n| 812P         | Efficacy and safety of two schemes of nivolumab (Nivo) and ipilimumab (Ipi) in MSI/dMMR metastatic colorectal cancer (mCRC): The PRODIGE-74 GERCOR NIPISAFE randomized non-comparative phase II trial                                                | Romain Cohen                 | Sorbonne University and Department of Medical Oncology, Saint-Antoine Hospital, Paris 75015, France.                                                                                                     |\n| 879eP        | Nivolumab and ipilimumab in anti-PD1-resistant MSI/dMMR metastatic colorectal cancer: Interim analysis of the GERCOR NIPIRESCUE phase II trial                                                                                                       | Romain Cohen                 | Sorbonne University and Department of Medical Oncology, Saint-Antoine Hospital, Paris 75015, France.                                                                                                     |\n| 831P         | Cadonilimab combined with FOLFOXIRI and bevacizumab as first-line treatment for microsatellite stable/proficient mismatch repair (MSS/pMMR) metastatic colorectal cancer (mCRC): Update result from a multicenter, phase II study (SYLT-026)         | Rongbo Lin                   | Department of Medical Oncology, Fujian Medical University Cancer Hospital and Fujian Cancer Hospital, Fuzhou, Fujian, People's Republic of China.                                                        |\n| 778P         | Prognostic significance of tumor deposits in locally advanced rectal cancer: Post-hoc analysis of a phase III trial                                                                                                                                  | RunKai Cai                   | Department of Medical Oncology, Department of General Surgery, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou 510655, China                                                            |\n"
  },
  "head_and_neck_cancer": {
    "regimen_groups": [
      {
        "regimen": "Pembrolizumab",
        "count": 18,
        "examples": [
          "1320O",
          "1323MO",
          "1426P",
          "1515MO",
          "1441TiP"
        ]
      },
      {
        "regimen": "Nivolumab",
        "count": 9,
        "examples": [
          "2613MO",
          "1371P",
          "1403P",
          "LBA59",
          "2687MO"
        ]
      },
      {
        "regimen": "Cetuximab",
        "count": 6,
        "examples": [
          "1441TiP",
          "1395P",
          "1360P",
          "1422P",
          "1346P"
        ]
      }
    ],
    "unmet_need_signals": [
      {
        "category": "Post-progression",
        "count": 15
      },
      {
        "category": "Resistance mechanisms",
        "count": 9
      },
      {
        "category": "Elderly patients",
        "count": 3
      },
      {
        "category": "Brain metastases",
        "count": 2
      },
      {
        "category": "Sequencing strategies",
        "count": 2
      },
      {
        "category": "Rare mutations",
        "count": 1
      }
    ],
    "biomarker_moa": {
      "columns": [
        "Biomarker/MOA",
        "# Studies",
        "Identifiers",
        "Sessions"
      ],
      "rows": [
        {
          "Biomarker/MOA": "PD-L1",
          "# Studies": 12,
          "Identifiers": "1348MO, 1323MO, 1515MO, LBA48, 200eP, LBA22, 1851MO, 323MO, 1415P, 1325MO, +2 more",
          "Sessions": "Mini Oral Session, Proffered Paper, ePoster, +1 more"
        },
        {
          "Biomarker/MOA": "HER2",
          "# Studies": 12,
          "Identifiers": "294MO, , 486MO, LBA25, 504P, 485MO, 737MO, 489MO, 487MO, 293MO, +2 more",
          "Sessions": "Mini Oral Session, Industry-Sponsored S, Poster, +1 more"
        },
        {
          "Biomarker/MOA": "PD-1",
          "# Studies": 8,
          "Identifiers": "1372P, LBA48, 1522MO, 1298eP, 1422P, 1428P, 1411P, 1347P",
          "Sessions": "Poster, Proffered Paper, Mini Oral Session, +1 more"
        },
        {
          "Biomarker/MOA": "KRAS",
          "# Studies": 5,
          "Identifiers": "1016eTiP, 916O, 926MO, 927MO, 1846MO",
          "Sessions": "ePoster, Proffered Paper, Mini Oral Session"
        },
        {
          "Biomarker/MOA": "ctDNA",
          "# Studies": 5,
          "Identifiers": "732MO, 1379P, LBA70, 666MO, 1396P",
          "Sessions": "Mini Oral Session, Poster"
        },
        {
          "Biomarker/MOA": "BRAF",
          "# Studies": 4,
          "Identifiers": "727MO, 1849MO, 728MO, 720eP",
          "Sessions": "Mini Oral Session, ePoster"
        },
        {
          "Biomarker/MOA": "EGFR",
          "# Studies": 3,
          "Identifiers": "1817MO, 1413P, 728MO",
          "Sessions": "Mini Oral Session, Poster"
        },
        {
          "Biomarker/MOA": "CDK4",
          "# Studies": 3,
          "Identifiers": "486MO, 487MO, 652eTiP",
          "Sessions": "Mini Oral Session, ePoster"
        },
        {
          "Biomarker/MOA": "CDK4/6",
          "# Studies": 3,
          "Identifiers": "486MO, 487MO, 652eTiP",
          "Sessions": "Mini Oral Session, ePoster"
        },
        {
          "Biomarker/MOA": "PARP",
          "# Studies": 2,
          "Identifiers": "LBA45, 1338P",
          "Sessions": "Mini Oral Session, Poster"
        },
        {
          "Biomarker/MOA": "FGFR",
          "# Studies": 2,
          "Identifiers": "81MO, 1456eP",
          "Sessions": "Mini Oral Session, ePoster"
        },
        {
          "Biomarker/MOA": "MSI-H",
          "# Studies": 1,
          "Identifiers": "925MO",
          "Sessions": "Mini Oral Session"
        },
        {
          "Biomarker/MOA": "MET",
          "# Studies": 1,
          "Identifiers": "2610MO",
          "Sessions": "Mini Oral Session"
        },
        {
          "Biomarker/MOA": "FGFR3",
          "# Studies": 1,
          "Identifiers": "3070MO",
          "Sessions": "Mini Oral Session"
        },
        {
          "Biomarker/MOA": "TIGIT",
          "# Studies": 1,
          "Identifiers": "1415P",
          "Sessions": "Poster"
        },
        {
          "Biomarker/MOA": "BRCA",
          "# Studies": 1,
          "Identifiers": "2805MO",
          "Sessions": "Mini Oral Session"
        },
        {
          "Biomarker/MOA": "VEGF",
          "# Studies": 1,
          "Identifiers": "1466eTiP",
          "Sessions": "ePoster"
        },
        {
          "Biomarker/MOA": "MSI",
          "# Studies": 1,
          "Identifiers": "925MO",
          "Sessions": "Mini Oral Session"
        },
        {
          "Biomarker/MOA": "dMMR",
          "# Studies": 1,
          "Identifiers": "925MO",
          "Sessions": "Mini Oral Session"
        },
        {
          "Biomarker/MOA": "AKT",
          "# Studies": 1,
          "Identifiers": "504P",
          "Sessions": "Poster"
        },
        {
          "Biomarker/MOA": "PI3K",
          "# Studies": 1,
          "Identifiers": "LBA26",
          "Sessions": "Mini Oral Session"
        },
        {
          "Biomarker/MOA": "PIK3CA",
          "# Studies": 1,
          "Identifiers": "116MO",
          "Sessions": "Mini Oral Session"
        },
        {
          "Biomarker/MOA": "mTOR",
          "# Studies": 1,
          "Identifiers": "652eTiP",
          "Sessions": "ePoster"
        },
        {
          "Biomarker/MOA": "CD20",
          "# Studies": 1,
          "Identifiers": "1298eP",
          "Sessions": "ePoster"
        },
        {
          "Biomarker/MOA": "CD19",
          "# Studies": 1,
          "Identifiers": "1246MO",
          "Sessions": "Mini Oral Session"
        },
        {
          "Biomarker/MOA": "DLL3",
          "# Studies": 1,
          "Identifiers": "1707MO",
          "Sessions": "Mini Oral Session"
        },
        {
          "Biomarker/MOA": "NaPi2b",
          "# Studies": 1,
          "Identifiers": "LBA43",
          "Sessions": "Mini Oral Session"
        }
      ]
    },
    "novel_studies": {
      "columns": [
        "Identifier",
        "Title",
        "Speakers",
        "Affiliation"
      ],
      "rows": [
        {
          "Identifier": "1337P",
          "Title": "Dose-finding and efficacy confirmation trial of the superselective intra-arterial cisplatin and concomitant radiotherapy for locally advanced maxillary sinus cancer (JCOG1212): Results of the efficacy confirmation phase in the T4b cohort",
          "Speakers": "Akihiro Homma",
          "Affiliation": "Department of Otolaryngology-Head & Neck Surgery, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan."
        },
        {
          "Identifier": "1016eTiP",
          "Title": "A first-in-human phase I study of LY4066434, a potent and orally bioavailable pan-KRAS inhibitor, in KRAS-mutant solid tumors (Trial in Progress)",
          "Speakers": "Shigehisa Kitano",
          "Affiliation": "Department of Advanced Medical Development, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan."
        },
        {
          "Identifier": "3070MO",
          "Title": "Phase I study of LY3866288, a potent, highly isoform-selective FGFR3 inhibitor in FGFR3-altered advanced solid tumors (FORAGER-1): Dose optimization",
          "Speakers": "Alexandra Drakaki",
          "Affiliation": "19University of California, Los Angeles Medical Center, CA, USA."
        },
        {
          "Identifier": "1038MO",
          "Title": "Single-dose carboplatin and involved-node radiotherapy for seminoma stage IIA/B: Long-term follow-up from the international multicenter phase II trial SAKK 01/10",
          "Speakers": "Alexandros Papachristofilou",
          "Affiliation": "Department of Radiation Oncology, University Hospital Basel, Basel, Switzerland."
        },
        {
          "Identifier": "1018eTiP",
          "Title": "A phase I trial of RGT-61159, an oral MYB transcription factor inhibitor, for patients with relapsed/refractory (R/R) adenoid cystic carcinoma (ACC) and colorectal cancer (CRC)",
          "Speakers": "Renata Ferrarotto",
          "Affiliation": "The University of Texas Anderson Cancer Center, Houston, Texas, USA."
        },
        {
          "Identifier": "1709MO",
          "Title": "Multi-center NCI-sponsored phase I study of triapine in combination with 177Lu-dotatate in patients with well-differentiated gastroenteropancreatic neuroendocrine tumours (GEP-NETs)",
          "Speakers": "Aman Chauhan",
          "Affiliation": "Division of Medical Oncology, Department of Medicine, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA."
        },
        {
          "Identifier": "1348MO",
          "Title": "SKYSCRAPER-09: Phase II, randomised study of tiragolumab (tira) + atezolizumab (atezo) and atezo + placebo (pbo) as first-line (1L) treatment in patients (pts) with recurrent/metastatic PD-L1+ squamous cell carcinoma of the head and neck (R/M SCCHN)",
          "Speakers": "Amanda Psyrri",
          "Affiliation": "Medical Oncology Unit, 2nd Department of Internal Medicine-Propaedeutic, Medical School, National and Kapodistrian University of Athens, Attikon University Hospital, Chaidari, Greece."
        },
        {
          "Identifier": "1065MO",
          "Title": "First-in-human study of AZD5335, a folate receptor  (FR)-targeted antibody-drug conjugate, in patients with platinum-resistant recurrent ovarian cancer",
          "Speakers": "Ana Oaknin",
          "Affiliation": "Medical Oncology Service, Vall d'Hebron Institute of Oncology, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain."
        },
        {
          "Identifier": "LBA43",
          "Title": "NAPISTAR 1-01: A Phase 1 dose escalation study of TUB-040, a novel NaPi2b-targeting exatecan antibody-drug conjugate (ADC) in patients with platinum-resistant ovarian (PROC) high grade serous carcinoma (HGSC)",
          "Speakers": "Antonio Gonzalez-Martin",
          "Affiliation": "Department of Medical Oncology and Program in Solid Tumors Cima-Universidad de Navarra, Cancer Center Clínica Universidad de Navarra (CCUN), Madrid, Spain."
        },
        {
          "Identifier": "2693MO",
          "Title": "COTESARC: A multicentre, open-label, phase I-II evaluating the combination of MEK and PDL-1 inhibitors in patients with advanced soft tissue sarcoma (STS)",
          "Speakers": "Armelle Dufresne",
          "Affiliation": "Department of Medical Oncology, Léon Bérard Cancer Center, Lyon, France."
        },
        {
          "Identifier": "2384MO",
          "Title": "First interim efficacy analysis of the phase I/II PETRANHA trial of saruparib + androgen receptor pathway inhibitors (ARPI) in patients (pts) with metastatic prostate cancer (mPC)",
          "Speakers": "Arun A. Azad",
          "Affiliation": "Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia"
        },
        {
          "Identifier": "1323MO",
          "Title": "ASPEN-03: A randomized phase II study of evorpacept in combination with pembrolizumab in patients with recurrent, unresectable or metastatic (R/M) PD-L1 positive head and neck squamous cell carcinoma (HNSCC)",
          "Speakers": "Bhumsuk Keam",
          "Affiliation": "Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea."
        },
        {
          "Identifier": "1372P",
          "Title": "A prospective, open and single-arm phase II clinical study of nab-paclitaxel combined with cisplatin and PD-1 inhibitor followed by concurrent chemoradiotherapy for locally advanced nasopharyngeal",
          "Speakers": "Bin Huang",
          "Affiliation": "Department of Urology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou"
        },
        {
          "Identifier": "1371P",
          "Title": "Nivolumab plus chemoradiotherapy sparing concurrent cisplatin in nasopharyngeal carcinoma (NPC): Social reintegration and patient-reported outcomes (PROs) in quality-of-life (QoL) and tolerability from a phase II PLATINUM trial",
          "Speakers": "Cheng Xu",
          "Affiliation": "Department of Radiation Oncology, Ruijin Hospital, Shanghai Jiao Tong University Medical School of medicine, Shanghai, China."
        },
        {
          "Identifier": "1707MO",
          "Title": "A phase II dose expansion study of ZG006, a trispecific T cell engager targeting DLL3/DLL3/CD3, as monotherapy in patients with refractory neuroendocrine carcinoma",
          "Speakers": "Chuanhua Zhao",
          "Affiliation": "Department of Oncology, The Fifth Medical Center, Chinese PLA General Hospital, Beijing, China."
        },
        {
          "Identifier": "1603MO",
          "Title": "Analysis of second primary cutaneous squamous cell carcinoma (CSCC) tumors (SPTs) reported during the C-POST trial, a randomized phase III study of adjuvant cemiplimab vs placebo (pbo) for high-risk CSCC",
          "Speakers": "Danny Rischin",
          "Affiliation": "Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia, Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia."
        },
        {
          "Identifier": "1390P",
          "Title": "Updated long term efficacy results of phase II study for becotatug vedotin combined with pucotenlimab in recurrent or metastatic nasopharyngeal carcinoma (R/M-NPC)",
          "Speakers": "Danyun Ruan",
          "Affiliation": "Department of Medical Oncology and Guangdong Key Laboratory of Liver Disease, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, People's Republic of China."
        },
        {
          "Identifier": "LBA26",
          "Title": "A phase 1/2 trial of LY4064809 (STX-478), a pan-mutant-selective PI3K inhibitor: Updated PIKALO-1 results",
          "Speakers": "Dejan Juric",
          "Affiliation": "Massachusetts General Cancer Center and Department of Medicine, Harvard Medical School, Boston, MA, USA."
        },
        {
          "Identifier": "LBA48",
          "Title": "BURAN: A phase III study of buparlisib (BUP) plus paclitaxel (PAC) in patients with PD-1(PD-L1)-pretreated recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).",
          "Speakers": "Denis Soulieres",
          "Affiliation": "Centre Hospitalier de l'Université de Montréal, Montreal, QC H3C 3J7, Canada."
        },
        {
          "Identifier": "1441TiP",
          "Title": "An open-label, phase Ib trial to assess the safety and efficacy of SIRP monoclonal antibody BI 770371 in combination with pembrolizumab with or without cetuximab compared with pembrolizumab monotherapy for the first-line treatment of patients with head and neck squamous cell carcinoma (NCT06806852)",
          "Speakers": "Simon Laban",
          "Affiliation": "Department of Otorhinolaryngology and Head and Neck Surgery, Ulm University Medical Center and Comprehensive Cancer Center Ulm, Ulm, Germany."
        },
        {
          "Identifier": "662MO",
          "Title": "Phase I/IIa study of concomitant radiotherapy with olaparib and temozolomide (TMZ) in unresectable high-grade gliomas patients (pts): Results from the phase IIa (OLA-TMZ-RTE-01)",
          "Speakers": "DInu STEFAN",
          "Affiliation": "Department of Radiation Oncology, François Baclesse Comprehensive Cancer Center, Caen, France."
        },
        {
          "Identifier": "1520MO",
          "Title": "Phase I first-in-human study of a novel anti-CD137 switch antibody agonist STA551 (STA) as monotherapy and in combination with atezolizumab (atezo) in patients (pts) with advanced solid tumors",
          "Speakers": "Diogo Silva",
          "Affiliation": "Center for Drug Discovery and Innovative Medicines (MedInUP) and RISE-Health: Health Research Network, Portugal."
        },
        {
          "Identifier": "1443TiP",
          "Title": "EORTC 2014-HNCG PROLoNg: Pembrolizumab and radiotherapy for oligometastatic squamous cell carcinoma of the head and neck, randomized phase III trial",
          "Speakers": "Irene Brana",
          "Affiliation": "Department of Medical Oncology, Vall d'Hebron Barcelona Hospital Campus, Spain."
        },
        {
          "Identifier": "1465eTiP",
          "Title": "Tislelizumab combined with chemotherapy followed by radiotherapy/adaptive surgery for larynx preservation in locally advanced laryngeal and hypopharyngeal cancer: A single-arm phase II study",
          "Speakers": "Defeng Chen",
          "Affiliation": "Department of Gastrointestinal, The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, Guangxi, China."
        },
        {
          "Identifier": "1519MO",
          "Title": "Phase Ia results for systemic STING agonist BI 1703880 plus ezabenlimab in patients (pts) with advanced solid tumors: Progress to date",
          "Speakers": "Eileen E. Parkes",
          "Affiliation": "Department of Oncology, Oxford University, Oxford, UK."
        },
        {
          "Identifier": "919O",
          "Title": "A first-in-human study of oral IAG933 in adult patients with advanced mesothelioma and other solid tumours",
          "Speakers": "Elena Garralda",
          "Affiliation": "Department of Medical Oncology, Vall d'Hebron Barcelona Hospital Campus, Spain."
        },
        {
          "Identifier": "1522MO",
          "Title": "A phase I study of INCA33890, a PD-1/TGFR2 bispecific antibody, for advanced solid tumours",
          "Speakers": "Elena Garralda",
          "Affiliation": "Department of Medical Oncology, Vall d'Hebron Barcelona Hospital Campus, Spain."
        },
        {
          "Identifier": "1466eTiP",
          "Title": "Phase II trial of TU2218, TGF-RI and VEGF-R2 dual inhibitor in combination with pembrolizumab in patients with head and neck cancer",
          "Speakers": "Sung-Bae Kim",
          "Affiliation": "Department of Medical Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea."
        },
        {
          "Identifier": "1392P",
          "Title": "The impede phase II trial: Avelumab (A) in high-risk oral potentially malignant disorders (OPMDs) for prevention of malignant transformation",
          "Speakers": "Erika Stucchi",
          "Affiliation": "Medical Oncology Unit, Bergamo, Italy, Department of Biomedical Sciences, Humanitas University, Rozzano, Italy."
        },
        {
          "Identifier": "1510TiP",
          "Title": "A phase II study of a patented oral fecal microbiota capsule for reprogramming immunity in advanced hepatocellular carcinoma (HCC) resistant to immune checkpoint inhibitors (ICIs)",
          "Speakers": "Cineng Xu",
          "Affiliation": "College of Animal Science and National Engineering Research Center for Breeding Swine Industry, South China Agricultural University, Guangdong, P.R. China."
        }
      ]
    },
    "table_context": "**BIOMARKER/MOA TABLE:**\n| Biomarker/MOA   |   # Studies | Identifiers                                                                        | Sessions                                                 |\n|:----------------|------------:|:-----------------------------------------------------------------------------------|:---------------------------------------------------------|\n| PD-L1           |          12 | 1348MO, 1323MO, 1515MO, LBA48, 200eP, LBA22, 1851MO, 323MO, 1415P, 1325MO, +2 more | Mini Oral Session, Proffered Paper, ePoster, +1 more     |\n| HER2            |          12 | 294MO, , 486MO, LBA25, 504P, 485MO, 737MO, 489MO, 487MO, 293MO, +2 more            | Mini Oral Session, Industry-Sponsored S, Poster, +1 more |\n| PD-1            |           8 | 1372P, LBA48, 1522MO, 1298eP, 1422P, 1428P, 1411P, 1347P                           | Poster, Proffered Paper, Mini Oral Session, +1 more      |\n| KRAS            |           5 | 1016eTiP, 916O, 926MO, 927MO, 1846MO                                               | ePoster, Proffered Paper, Mini Oral Session              |\n| ctDNA           |           5 | 732MO, 1379P, LBA70, 666MO, 1396P                                                  | Mini Oral Session, Poster                                |\n| BRAF            |           4 | 727MO, 1849MO, 728MO, 720eP                                                        | Mini Oral Session, ePoster                               |\n| EGFR            |           3 | 1817MO, 1413P, 728MO                                                               | Mini Oral Session, Poster                                |\n| CDK4            |           3 | 486MO, 487MO, 652eTiP                                                              | Mini Oral Session, ePoster                               |\n| CDK4/6          |           3 | 486MO, 487MO, 652eTiP                                                              | Mini Oral Session, ePoster                               |\n| PARP            |           2 | LBA45, 1338P                                                                       | Mini Oral Session, Poster                                |\n| FGFR            |           2 | 81MO, 1456eP                                                                       | Mini Oral Session, ePoster                               |\n| MSI-H           |           1 | 925MO                                                                              | Mini Oral Session                                        |\n| MET             |           1 | 2610MO                                                                             | Mini Oral Session                                        |\n| FGFR3           |           1 | 3070MO                                                                             | Mini Oral Session                                        |\n| TIGIT           |           1 | 1415P                                                                              | Poster                                                   |\n| BRCA            |           1 | 2805MO                                                                             | Mini Oral Session                                        |\n| VEGF            |           1 | 1466eTiP                                                                           | ePoster                                                  |\n| MSI             |           1 | 925MO                                                                              | Mini Oral Session                                        |\n| dMMR            |           1 | 925MO                                                                              | Mini Oral Session                                        |\n| AKT             |           1 | 504P                                                                               | Poster                                                   |\n| PI3K            |           1 | LBA26                                                                              | Mini Oral Session                                        |\n| PIK3CA          |           1 | 116MO                                                                              | Mini Oral Session                                        |\n| mTOR            |           1 | 652eTiP                                                                            | ePoster                                                  |\n| CD20            |           1 | 1298eP                                                                             | ePoster                                                  |\n| CD19            |           1 | 1246MO                                                                             | Mini Oral Session                                        |\n| DLL3            |           1 | 1707MO                                                                             | Mini Oral Session                                        |\n| NaPi2b          |           1 | LBA43                                                                              | Mini Oral Session                                        |\n\n**NOVEL/EARLY-PHASE STUDIES:**\n| Identifier   | Title                                                                                                                                                                                                                                                                                                       | Speakers                    | Affiliation                                                                                                                                                                             |\n|:-------------|:------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|:----------------------------|:----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n| 1337P        | Dose-finding and efficacy confirmation trial of the superselective intra-arterial cisplatin and concomitant radiotherapy for locally advanced maxillary sinus cancer (JCOG1212): Results of the efficacy confirmation phase in the T4b cohort                                                               | Akihiro Homma               | Department of Otolaryngology-Head & Neck Surgery, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan.                                             |\n| 1016eTiP     | A first-in-human phase I study of LY4066434, a potent and orally bioavailable pan-KRAS inhibitor, in KRAS-mutant solid tumors (Trial in Progress)                                                                                                                                                           | Shigehisa Kitano            | Department of Advanced Medical Development, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.                                                     |\n| 3070MO       | Phase I study of LY3866288, a potent, highly isoform-selective FGFR3 inhibitor in FGFR3-altered advanced solid tumors (FORAGER-1): Dose optimization                                                                                                                                                        | Alexandra Drakaki           | 19University of California, Los Angeles Medical Center, CA, USA.                                                                                                                        |\n| 1038MO       | Single-dose carboplatin and involved-node radiotherapy for seminoma stage IIA/B: Long-term follow-up from the international multicenter phase II trial SAKK 01/10                                                                                                                                           | Alexandros Papachristofilou | Department of Radiation Oncology, University Hospital Basel, Basel, Switzerland.                                                                                                        |\n| 1018eTiP     | A phase I trial of RGT-61159, an oral MYB transcription factor inhibitor, for patients with relapsed/refractory (R/R) adenoid cystic carcinoma (ACC) and colorectal cancer (CRC)                                                                                                                            | Renata Ferrarotto           | The University of Texas Anderson Cancer Center, Houston, Texas, USA.                                                                                                                    |\n| 1709MO       | Multi-center NCI-sponsored phase I study of triapine in combination with 177Lu-dotatate in patients with well-differentiated gastroenteropancreatic neuroendocrine tumours (GEP-NETs)                                                                                                                       | Aman Chauhan                | Division of Medical Oncology, Department of Medicine, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA.                                                       |\n| 1348MO       | SKYSCRAPER-09: Phase II, randomised study of tiragolumab (tira) + atezolizumab (atezo) and atezo + placebo (pbo) as first-line (1L) treatment in patients (pts) with recurrent/metastatic PD-L1+ squamous cell carcinoma of the head and neck (R/M SCCHN)                                                   | Amanda Psyrri               | Medical Oncology Unit, 2nd Department of Internal Medicine-Propaedeutic, Medical School, National and Kapodistrian University of Athens, Attikon University Hospital, Chaidari, Greece. |\n| 1065MO       | First-in-human study of AZD5335, a folate receptor  (FR)-targeted antibody-drug conjugate, in patients with platinum-resistant recurrent ovarian cancer                                                                                                                                                     | Ana Oaknin                  | Medical Oncology Service, Vall d'Hebron Institute of Oncology, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.                                                               |\n| LBA43        | NAPISTAR 1-01: A Phase 1 dose escalation study of TUB-040, a novel NaPi2b-targeting exatecan antibody-drug conjugate (ADC) in patients with platinum-resistant ovarian (PROC) high grade serous carcinoma (HGSC)                                                                                            | Antonio Gonzalez-Martin     | Department of Medical Oncology and Program in Solid Tumors Cima-Universidad de Navarra, Cancer Center Clínica Universidad de Navarra (CCUN), Madrid, Spain.                             |\n| 2693MO       | COTESARC: A multicentre, open-label, phase I-II evaluating the combination of MEK and PDL-1 inhibitors in patients with advanced soft tissue sarcoma (STS)                                                                                                                                                  | Armelle Dufresne            | Department of Medical Oncology, Léon Bérard Cancer Center, Lyon, France.                                                                                                                |\n| 2384MO       | First interim efficacy analysis of the phase I/II PETRANHA trial of saruparib + androgen receptor pathway inhibitors (ARPI) in patients (pts) with metastatic prostate cancer (mPC)                                                                                                                         | Arun A. Azad                | Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia                                                                                               |\n| 1323MO       | ASPEN-03: A randomized phase II study of evorpacept in combination with pembrolizumab in patients with recurrent, unresectable or metastatic (R/M) PD-L1 positive head and neck squamous cell carcinoma (HNSCC)                                                                                             | Bhumsuk Keam                | Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea.                                                                                          |\n| 1372P        | A prospective, open and single-arm phase II clinical study of nab-paclitaxel combined with cisplatin and PD-1 inhibitor followed by concurrent chemoradiotherapy for locally advanced nasopharyngeal                                                                                                        | Bin Huang                   | Department of Urology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou                                                                                               |\n| 1371P        | Nivolumab plus chemoradiotherapy sparing concurrent cisplatin in nasopharyngeal carcinoma (NPC): Social reintegration and patient-reported outcomes (PROs) in quality-of-life (QoL) and tolerability from a phase II PLATINUM trial                                                                         | Cheng Xu                    | Department of Radiation Oncology, Ruijin Hospital, Shanghai Jiao Tong University Medical School of medicine, Shanghai, China.                                                           |\n| 1707MO       | A phase II dose expansion study of ZG006, a trispecific T cell engager targeting DLL3/DLL3/CD3, as monotherapy in patients with refractory neuroendocrine carcinoma                                                                                                                                         | Chuanhua Zhao               | Department of Oncology, The Fifth Medical Center, Chinese PLA General Hospital, Beijing, China.                                                                                         |\n| 1603MO       | Analysis of second primary cutaneous squamous cell carcinoma (CSCC) tumors (SPTs) reported during the C-POST trial, a randomized phase III study of adjuvant cemiplimab vs placebo (pbo) for high-risk CSCC                                                                                                 | Danny Rischin               | Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia, Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia.         |\n| 1390P        | Updated long term efficacy results of phase II study for becotatug vedotin combined with pucotenlimab in recurrent or metastatic nasopharyngeal carcinoma (R/M-NPC)                                                                                                                                         | Danyun Ruan                 | Department of Medical Oncology and Guangdong Key Laboratory of Liver Disease, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, People's Republic of China.           |\n| LBA26        | A phase 1/2 trial of LY4064809 (STX-478), a pan-mutant-selective PI3K inhibitor: Updated PIKALO-1 results                                                                                                                                                                                                   | Dejan Juric                 | Massachusetts General Cancer Center and Department of Medicine, Harvard Medical School, Boston, MA, USA.                                                                                |\n| LBA48        | BURAN: A phase III study of buparlisib (BUP) plus paclitaxel (PAC) in patients with PD-1(PD-L1)-pretreated recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).                                                                                                                        | Denis Soulieres             | Centre Hospitalier de l'Université de Montréal, Montreal, QC H3C 3J7, Canada.                                                                                                           |\n| 1441TiP      | An open-label, phase Ib trial to assess the safety and efficacy of SIRP monoclonal antibody BI 770371 in combination with pembrolizumab with or without cetuximab compared with pembrolizumab monotherapy for the first-line treatment of patients with head and neck squamous cell carcinoma (NCT06806852) | Simon Laban                 | Department of Otorhinolaryngology and Head and Neck Surgery, Ulm University Medical Center and Comprehensive Cancer Center Ulm, Ulm, Germany.                                           |\n| 662MO        | Phase I/IIa study of concomitant radiotherapy with olaparib and temozolomide (TMZ) in unresectable high-grade gliomas patients (pts): Results from the phase IIa (OLA-TMZ-RTE-01)                                                                                                                           | DInu STEFAN                 | Department of Radiation Oncology, François Baclesse Comprehensive Cancer Center, Caen, France.                                                                                          |\n| 1520MO       | Phase I first-in-human study of a novel anti-CD137 switch antibody agonist STA551 (STA) as monotherapy and in combination with atezolizumab (atezo) in patients (pts) with advanced solid tumors                                                                                                            | Diogo Silva                 | Center for Drug Discovery and Innovative Medicines (MedInUP) and RISE-Health: Health Research Network, Portugal.                                                                        |\n| 1443TiP      | EORTC 2014-HNCG PROLoNg: Pembrolizumab and radiotherapy for oligometastatic squamous cell carcinoma of the head and neck, randomized phase III trial                                                                                                                                                        | Irene Brana                 | Department of Medical Oncology, Vall d'Hebron Barcelona Hospital Campus, Spain.                                                                                                         |\n| 1465eTiP     | Tislelizumab combined with chemotherapy followed by radiotherapy/adaptive surgery for larynx preservation in locally advanced laryngeal and hypopharyngeal cancer: A single-arm phase II study                                                                                                              | Defeng Chen                 | Department of Gastrointestinal, The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, Guangxi, China.                                                                     |\n| 1519MO       | Phase Ia results for systemic STING agonist BI 1703880 plus ezabenlimab in patients (pts) with advanced solid tumors: Progress to date                                                                                                                                                                      | Eileen E. Parkes            | Department of Oncology, Oxford University, Oxford, UK.                                                                                                                                  |\n| 919O         | A first-in-human study of oral IAG933 in adult patients with advanced mesothelioma and other solid tumours                                                                                                                                                                                                  | Elena Garralda              | Department of Medical Oncology, Vall d'Hebron Barcelona Hospital Campus, Spain.                                                                                                         |\n| 1522MO       | A phase I study of INCA33890, a PD-1/TGFR2 bispecific antibody, for advanced solid tumours                                                                                                                                                                                                                  | Elena Garralda              | Department of Medical Oncology, Vall d'Hebron Barcelona Hospital Campus, Spain.                                                                                                         |\n| 1466eTiP     | Phase II trial of TU2218, TGF-RI and VEGF-R2 dual inhibitor in combination with pembrolizumab in patients with head and neck cancer                                                                                                                                                                         | Sung-Bae Kim                | Department of Medical Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.                                                                 |\n| 1392P        | The impede phase II trial: Avelumab (A) in high-risk oral potentially malignant disorders (OPMDs) for prevention of malignant transformation                                                                                                                                                                | Erika Stucchi               | Medical Oncology Unit, Bergamo, Italy, Department of Biomedical Sciences, Humanitas University, Rozzano, Italy.                                                                         |\n| 1510TiP      | A phase II study of a patented oral fecal microbiota capsule for reprogramming immunity in advanced hepatocellular carcinoma (HCC) resistant to immune checkpoint inhibitors (ICIs)                                                                                                                         | Cineng Xu                   | College of Animal Science and National Engineering Research Center for Breeding Swine Industry, South China Agricultural University, Guangdong, P.R. China.                             |\n"
  },
  "nsclc,_metastatic": {
    "regimen_groups": [],
    "unmet_need_signals": [
      {
        "category": "Post-progression",
        "count": 127
      },
      {
        "category": "Sequencing strategies",
        "count": 58
      },
      {
        "category": "Resistance mechanisms",
        "count": 53
      },
      {
        "category": "Brain metastases",
        "count": 40
      },
      {
        "category": "Elderly patients",
        "count": 25
      },
      {
        "category": "Poor performance status",
        "count": 2
      },
      {
        "category": "Rare mutations",
        "count": 2
      }
    ],
    "biomarker_moa": {
      "columns": [
        "Biomarker/MOA",
        "# Studies",
        "Identifiers",
        "Sessions"
      ],
      "rows": [
        {
          "Biomarker/MOA": "HER2",
          "# Studies": 215,
          "Identifiers": "523P, 1015eTiP, 572P, , 219eP, 447eP, 520P, 294MO, 336P, 478P, +205 more",
          "Sessions": "Poster, ePoster, Industry-Sponsored S, +3 more"
        },
        {
          "Biomarker/MOA": "EGFR",
          "# Studies": 68,
          "Identifiers": "1948P, 853P, 677P, 2071eP, 891eP, LBA33, 3029eP, 2064eP, 249eP, , +58 more",
          "Sessions": "Poster, ePoster, Proffered Paper, +2 more"
        },
        {
          "Biomarker/MOA": "PD-L1",
          "# Studies": 53,
          "Identifiers": "1017eTiP, 1348MO, 1323MO, 1578P, 1879P, 1515MO, LBA48, 1795P, 200eP, LBA22, +43 more",
          "Sessions": "ePoster, Mini Oral Session, Poster, +2 more"
        },
        {
          "Biomarker/MOA": "ctDNA",
          "# Studies": 53,
          "Identifiers": "1634P, 194eP, 2783P, 2609P, 335P, 801P, 1893P, 732MO, 2521eP, 1132P, +43 more",
          "Sessions": "Poster, ePoster, Mini Oral Session, +1 more"
        },
        {
          "Biomarker/MOA": "PD-1",
          "# Studies": 47,
          "Identifiers": "1665P, LBA94, LBA61, 1564P, 2154P, 1372P, 1853MO, 1563P, 1545P, 2119P, +37 more",
          "Sessions": "Poster, Proffered Paper, Mini Oral Session, +1 more"
        },
        {
          "Biomarker/MOA": "BRAF",
          "# Studies": 43,
          "Identifiers": "2996P, 853P, 1682P, 891eP, , 687P, 1646P, , 2991P, 803P, +33 more",
          "Sessions": "Poster, ePoster, Industry-Sponsored S, +2 more"
        },
        {
          "Biomarker/MOA": "CDK4",
          "# Studies": 38,
          "Identifiers": "523P, 1730P, , 507P, 498P, 532P, 649eP, 497P, 486MO, 513P, +28 more",
          "Sessions": "Poster, Industry-Sponsored S, ePoster, +1 more"
        },
        {
          "Biomarker/MOA": "KRAS",
          "# Studies": 33,
          "Identifiers": "LBA84, 1016eTiP, 265eP, 1990P, 915O, , 1992P, 3029eP, 882eP, 743P, +23 more",
          "Sessions": "Proffered Paper, ePoster, Poster, +3 more"
        },
        {
          "Biomarker/MOA": "CDK4/6",
          "# Studies": 30,
          "Identifiers": "1730P, 507P, 532P, 649eP, 497P, 486MO, 513P, 372P, 522P, 500P, +20 more",
          "Sessions": "Poster, ePoster, Mini Oral Session"
        },
        {
          "Biomarker/MOA": "ALK",
          "# Studies": 23,
          "Identifiers": "972P, 1984P, 1828P, 1983P, LBA66, 996P, 1982P, 2567P, , 1979P, +13 more",
          "Sessions": "Poster, Mini Oral Session, Industry-Sponsored S, +2 more"
        },
        {
          "Biomarker/MOA": "MSI",
          "# Studies": 23,
          "Identifiers": "3058eP, 858P, 1756eP, 1529P, 801P, 802P, , , 2111P, 872eP, +13 more",
          "Sessions": "ePoster, Poster, Industry-Sponsored S, +3 more"
        },
        {
          "Biomarker/MOA": "dMMR",
          "# Studies": 17,
          "Identifiers": "3058eP, 1529P, 752P, , , 872eP, , 724O, 2168P, 925MO, +7 more",
          "Sessions": "ePoster, Poster, Industry-Sponsored S, +3 more"
        },
        {
          "Biomarker/MOA": "BRCA",
          "# Studies": 16,
          "Identifiers": "942P, 2463P, 2363P, 1071P, 3181eP, 500P, 2228P, 3059eP, 2805MO, 330P, +6 more",
          "Sessions": "Poster, ePoster, Mini Oral Session, +1 more"
        },
        {
          "Biomarker/MOA": "MET",
          "# Studies": 16,
          "Identifiers": "928P, 2074eP, 995P, 1795P, 1996P, 1967P, 1997P, 2610MO, 1955P, 932P, +6 more",
          "Sessions": "Poster, ePoster, Mini Oral Session, +1 more"
        },
        {
          "Biomarker/MOA": "BRCA1",
          "# Studies": 14,
          "Identifiers": "942P, 3181eP, 1107P, 328P, 325P, 329P, 943P, 327P, 330P, 275eP, +4 more",
          "Sessions": "Poster, ePoster"
        },
        {
          "Biomarker/MOA": "VEGF",
          "# Studies": 14,
          "Identifiers": "1017eTiP, , 1545P, 1466eTiP, 3049eP, 1860P, 792P, 1539P, 875eP, 1151P, +4 more",
          "Sessions": "ePoster, Industry-Sponsored S, Poster, +1 more"
        },
        {
          "Biomarker/MOA": "MSI-H",
          "# Studies": 12,
          "Identifiers": "1529P, 802P, , , 2111P, 872eP, 230eP, 925MO, 2141P, LBA29, +2 more",
          "Sessions": "Poster, Industry-Sponsored S, ePoster, +2 more"
        },
        {
          "Biomarker/MOA": "PIK3CA",
          "# Studies": 12,
          "Identifiers": "219eP, 529P, 526P, 735P, 116MO, 530P, 598P, LBA17, 619TiP, 548P, +2 more",
          "Sessions": "ePoster, Poster, Mini Oral Session, +1 more"
        },
        {
          "Biomarker/MOA": "PARP",
          "# Studies": 11,
          "Identifiers": "3147P, LBA45, 157P, 1093P, 1077P, 1338P, 2451P, 2270eP, 1133P, , +1 more",
          "Sessions": "Poster, Mini Oral Session, ePoster, +1 more"
        },
        {
          "Biomarker/MOA": "HRD",
          "# Studies": 10,
          "Identifiers": ", 326P, 1071P, 1146P, 1138P, 1130P, 471P, 1200P, 2731P, 1137P",
          "Sessions": "Educational Session, Poster"
        },
        {
          "Biomarker/MOA": "CLDN18.2",
          "# Studies": 9,
          "Identifiers": "945P, 2136P, 2137P, , , , LBA83, 2139P, 2138P",
          "Sessions": "Poster, Industry-Sponsored S, Mini Oral Session"
        },
        {
          "Biomarker/MOA": "FGFR",
          "# Studies": 8,
          "Identifiers": "1766eP, 284eP, 81MO, 1931P, 1932P, 288eTiP, 930P, 1456eP",
          "Sessions": "ePoster, Mini Oral Session, Poster"
        },
        {
          "Biomarker/MOA": "Nectin-4",
          "# Studies": 7,
          "Identifiers": "967P, 3095P, 963P, 1013eP, 3100P, 1412P, 3105P",
          "Sessions": "Poster, ePoster"
        },
        {
          "Biomarker/MOA": "DLL3",
          "# Studies": 7,
          "Identifiers": "1707MO, , 1731TiP, , 2776P, , 2775P",
          "Sessions": "Mini Oral Session, Industry-Sponsored S, Poster"
        },
        {
          "Biomarker/MOA": "ERBB2",
          "# Studies": 6,
          "Identifiers": "3102P, 3095P, 1146P, 348P, 2174P, 2003P",
          "Sessions": "Poster"
        },
        {
          "Biomarker/MOA": "CTLA-4",
          "# Studies": 6,
          "Identifiers": "1545P, 1685TiP, 1640P, 18P, 48eP, ",
          "Sessions": "Poster, ePoster, Symposium"
        },
        {
          "Biomarker/MOA": "PI3K",
          "# Studies": 6,
          "Identifiers": "1730P, LBA26, 466P, 619TiP, 602P, 195eP",
          "Sessions": "Poster, Mini Oral Session, ePoster"
        },
        {
          "Biomarker/MOA": "TIGIT",
          "# Studies": 5,
          "Identifiers": "1853MO, 1639P, 3061eP, 1885P, 1415P",
          "Sessions": "Mini Oral Session, Poster, ePoster"
        },
        {
          "Biomarker/MOA": "Claudin 18.2",
          "# Studies": 4,
          "Identifiers": "2144P, 2113P, 1725P, 2139P",
          "Sessions": "Poster"
        },
        {
          "Biomarker/MOA": "NTRK",
          "# Studies": 4,
          "Identifiers": "2013P, 171P, 687P, 2998P",
          "Sessions": "Poster"
        },
        {
          "Biomarker/MOA": "ROS1",
          "# Studies": 4,
          "Identifiers": "1988P, 1986P, 2027TiP, 1987MO",
          "Sessions": "Poster, Mini Oral Session"
        },
        {
          "Biomarker/MOA": "IDH1",
          "# Studies": 4,
          "Identifiers": "2749eP, 695P, 2748eP, 2745eP",
          "Sessions": "ePoster, Poster"
        },
        {
          "Biomarker/MOA": "CTC",
          "# Studies": 4,
          "Identifiers": "LBA80, 190eP, 2394P, 1813eP",
          "Sessions": "Proffered Paper, ePoster, Poster"
        },
        {
          "Biomarker/MOA": "FGFR3",
          "# Studies": 3,
          "Identifiers": "3070MO, 3102P, 3098P",
          "Sessions": "Mini Oral Session, Poster"
        },
        {
          "Biomarker/MOA": "AKT",
          "# Studies": 3,
          "Identifiers": "504P, 602P, 2701P",
          "Sessions": "Poster"
        },
        {
          "Biomarker/MOA": "TMB",
          "# Studies": 3,
          "Identifiers": "139P, 1713P, 1980P",
          "Sessions": "Poster"
        },
        {
          "Biomarker/MOA": "B7-H3",
          "# Studies": 3,
          "Identifiers": "950P, 2720P, 958P",
          "Sessions": "Poster"
        },
        {
          "Biomarker/MOA": "DDR",
          "# Studies": 3,
          "Identifiers": ", 988P, ",
          "Sessions": "Symposium, Poster, Educational Session"
        },
        {
          "Biomarker/MOA": "RET",
          "# Studies": 3,
          "Identifiers": "1999P, 2000P, 2998P",
          "Sessions": "Poster"
        },
        {
          "Biomarker/MOA": "HER3",
          "# Studies": 3,
          "Identifiers": "1142P, 921MO, 933P",
          "Sessions": "Poster, Mini Oral Session"
        },
        {
          "Biomarker/MOA": "TROP-2",
          "# Studies": 2,
          "Identifiers": "375P, 653eTiP",
          "Sessions": "Poster, ePoster"
        },
        {
          "Biomarker/MOA": "FGFR2",
          "# Studies": 2,
          "Identifiers": "140P, 2158P",
          "Sessions": "Poster"
        },
        {
          "Biomarker/MOA": "mTOR",
          "# Studies": 2,
          "Identifiers": "226eP, 652eTiP",
          "Sessions": "ePoster"
        },
        {
          "Biomarker/MOA": "CD19",
          "# Studies": 2,
          "Identifiers": "1240O, 1246MO",
          "Sessions": "Proffered Paper, Mini Oral Session"
        },
        {
          "Biomarker/MOA": "CEACAM5",
          "# Studies": 2,
          "Identifiers": "65eP, 962P",
          "Sessions": "ePoster, Poster"
        },
        {
          "Biomarker/MOA": "NRG1",
          "# Studies": 2,
          "Identifiers": "194eP, 1993P",
          "Sessions": "ePoster, Poster"
        },
        {
          "Biomarker/MOA": "ATR",
          "# Studies": 2,
          "Identifiers": "939P, 618TiP",
          "Sessions": "Poster"
        },
        {
          "Biomarker/MOA": "VEGFR",
          "# Studies": 2,
          "Identifiers": "2607P, 214eP",
          "Sessions": "Poster, ePoster"
        },
        {
          "Biomarker/MOA": "BRCA2",
          "# Studies": 2,
          "Identifiers": "1145P, 328P",
          "Sessions": "Poster"
        },
        {
          "Biomarker/MOA": "LAG-3",
          "# Studies": 1,
          "Identifiers": "1857P",
          "Sessions": "Poster"
        },
        {
          "Biomarker/MOA": "FGFR1",
          "# Studies": 1,
          "Identifiers": "2067eP",
          "Sessions": "ePoster"
        },
        {
          "Biomarker/MOA": "ATM",
          "# Studies": 1,
          "Identifiers": "472P",
          "Sessions": "Poster"
        },
        {
          "Biomarker/MOA": "VEGFR2",
          "# Studies": 1,
          "Identifiers": "195eP",
          "Sessions": "ePoster"
        },
        {
          "Biomarker/MOA": "WNT",
          "# Studies": 1,
          "Identifiers": "2713P",
          "Sessions": "Poster"
        },
        {
          "Biomarker/MOA": "CD38",
          "# Studies": 1,
          "Identifiers": "1290P",
          "Sessions": "Poster"
        },
        {
          "Biomarker/MOA": "IDH2",
          "# Studies": 1,
          "Identifiers": "2748eP",
          "Sessions": "ePoster"
        },
        {
          "Biomarker/MOA": "CD20",
          "# Studies": 1,
          "Identifiers": "1298eP",
          "Sessions": "ePoster"
        },
        {
          "Biomarker/MOA": "NaPi2b",
          "# Studies": 1,
          "Identifiers": "LBA43",
          "Sessions": "Mini Oral Session"
        }
      ]
    },
    "novel_studies": {
      "columns": [
        "Identifier",
        "Title",
        "Speakers",
        "Affiliation"
      ],
      "rows": [
        {
          "Identifier": "2388P",
          "Title": "Results from the phase Ib dose escalation of 212Pb-ADVC001 in PSMA-positive metastatic castration-resistant prostate cancer (mCRPC): The theraPb trial",
          "Speakers": "Aaron R. Hansen",
          "Affiliation": "Department of Medicine, University of Queensland, Brisbane, QLD 4072, Australia."
        },
        {
          "Identifier": "775P",
          "Title": "Sequencing neoadjuvant chemotherapy and short course radiation therapy in locally advanced rectal cancer: A phase II randomized controlled trial [SPADE study]",
          "Speakers": "Abhishek Shinghal",
          "Affiliation": "Department of Radiation Oncology, Mahamana Pandit Madan Mohan Malaviya Cancer Centre and Homi Bhabha Cancer Hospital, Tata Memorial Centre, Homi Bhabha National Institute, Varanasi, India."
        },
        {
          "Identifier": "2604P",
          "Title": "Farnesyltransferase inhibitor (FTI) KO-2806 in combination with cabozantinib (cabo) in renal cell carcinoma (RCC): Preliminary results from FIT-001 phase I trial",
          "Speakers": "Adanma Ayanambakkam",
          "Affiliation": "University of Oklahoma Stephenson Cancer Center, OK"
        },
        {
          "Identifier": "1000TiP",
          "Title": "Novel next generation PARP1-selective and CNS penetrant inhibitor DSB2455: A phase Ia/Ib open label, multi-centre dose escalation study with expansion cohorts to assess the safety, tolerability, and activity as monotherapy in participants with advanced malignancies",
          "Speakers": "Ramon Yarza",
          "Affiliation": "START-CIOCC, University Hospital HM Sanchinarro, Madrid, Spain."
        },
        {
          "Identifier": "1001TiP",
          "Title": "Raludotatug deruxtecan in participants with gastrointestinal cancers: Phase II REJOICE-GI01 trial",
          "Speakers": "Makoto Ueno",
          "Affiliation": "Department of Gastroenterology, Hepatobiliary and Pancreatic Medical Oncology Division Kanagawa Cancer Center Yokohama Japan."
        },
        {
          "Identifier": "1015eTiP",
          "Title": "Beamion BCGC-1: A phase Ib/II, randomized, open-label, multicenter trial of oral zongertinib, alone or in combination, for the treatment of advanced HER2-positive metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC)",
          "Speakers": "Sara A. Hurvitz",
          "Affiliation": "University of Washington Fred Hutchinson Cancer Center, Seattle, WA, USA."
        },
        {
          "Identifier": "1337P",
          "Title": "Dose-finding and efficacy confirmation trial of the superselective intra-arterial cisplatin and concomitant radiotherapy for locally advanced maxillary sinus cancer (JCOG1212): Results of the efficacy confirmation phase in the T4b cohort",
          "Speakers": "Akihiro Homma",
          "Affiliation": "Department of Otolaryngology-Head & Neck Surgery, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan."
        },
        {
          "Identifier": "1016eTiP",
          "Title": "A first-in-human phase I study of LY4066434, a potent and orally bioavailable pan-KRAS inhibitor, in KRAS-mutant solid tumors (Trial in Progress)",
          "Speakers": "Shigehisa Kitano",
          "Affiliation": "Department of Advanced Medical Development, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan."
        },
        {
          "Identifier": "2227P",
          "Title": "Safety and clinical efficacy of cambritaxestat (IOA-289), a novel autotaxin inhibitor, plus gemcitabine and nab-paclitaxel (GnP) in patients with previously untreated metastatic pancreatic ductal adenocarcinoma (mPDAC)",
          "Speakers": "Alberto Quinzii",
          "Affiliation": "Digestive Molecular Clinical Oncology Research Unit, Verona, Italy."
        },
        {
          "Identifier": "1485P",
          "Title": "Atezolizumab plus bevacizumab before or after transarterial chemoembolization in hepatocellular carcinoma: Interim analysis of the DEMAND (AIO-HEP-0418) randomized phase II clinical trial",
          "Speakers": "Alexander B. Philipp",
          "Affiliation": "Department of Medicine II, University Hospital, LMU Munich, Munich, Germany."
        },
        {
          "Identifier": "1017eTiP",
          "Title": "A phase II trial of DB-1311/BNT324 (B7H3 ADC) combined with BNT327 (PD-L1 x VEGF-A bsAb) or DB-1305/BNT325 (TROP2 ADC) in advanced/metastatic solid tumors",
          "Speakers": "Ye Guo",
          "Affiliation": "Department of Oncology, Shanghai Dongfang Hospital, Tongji University, Shanghai, China."
        },
        {
          "Identifier": "2023P",
          "Title": "Phase Ib study of valemetostat in combination with datopotamab deruxtecan (Dato-DXd) in advanced non-squamous non-small cell lung cancer (NSCLC): Initial safety results",
          "Speakers": "Alexander I. Spira",
          "Affiliation": "Virginia Cancer Specialists, Fairfax, VA, USA."
        },
        {
          "Identifier": "1611P",
          "Title": "Pembrolizumab versus placebo as adjuvant therapy for resected stage IIB or IIC melanoma: 5-year follow-up of the phase III KEYNOTE-716 study",
          "Speakers": "Alexander M. Eggermont",
          "Affiliation": "University Medical Center Utrecht & Princess Maxima Center, Utrecht, Netherlands, Comprehensive Cancer Center Munchen of the Technical University Munich & Ludwig Maximilians University, Munich"
        },
        {
          "Identifier": "3070MO",
          "Title": "Phase I study of LY3866288, a potent, highly isoform-selective FGFR3 inhibitor in FGFR3-altered advanced solid tumors (FORAGER-1): Dose optimization",
          "Speakers": "Alexandra Drakaki",
          "Affiliation": "19University of California, Los Angeles Medical Center, CA, USA."
        },
        {
          "Identifier": "853P",
          "Title": "Landscape of anti-EGFR resistance mutations in RAS/BRAF-wild type left-sided metastatic colorectal cancer: First sequencing results of the phase III CRC01 prospective trial",
          "Speakers": "Alexandra Lebedeva",
          "Affiliation": "Institute for Personalized Oncology, Sechenov First Moscow State Medical University, Moscow 119048, Russia."
        },
        {
          "Identifier": "2274O",
          "Title": "Dissecting four decades of phase III randomised pharmacological interventions for primary cancer prevention to guide future developments: ESMO early detection and prevention task force",
          "Speakers": "Alexandre Xu-Vuillard",
          "Affiliation": "Gustave-Roussy, Villejuif, France, Sorbonne Université, Paris"
        },
        {
          "Identifier": "1038MO",
          "Title": "Single-dose carboplatin and involved-node radiotherapy for seminoma stage IIA/B: Long-term follow-up from the international multicenter phase II trial SAKK 01/10",
          "Speakers": "Alexandros Papachristofilou",
          "Affiliation": "Department of Radiation Oncology, University Hospital Basel, Basel, Switzerland."
        },
        {
          "Identifier": "1083P",
          "Title": "Platinum-based vs non-platinum chemotherapy in platinum-resistant relapsed ovarian cancer (PROC): A randomized phase II trial",
          "Speakers": "Alexey Rumyantsev",
          "Affiliation": "N.N. Blokhin National Medical Research Center of Oncology, Moscow, Russia."
        },
        {
          "Identifier": "2445P",
          "Title": "Phase I/II study of gedatolisib in combination with darolutamide in metastatic castration-resistant prostate cancer (mCRPC)",
          "Speakers": "Alice Bernard-Tessier",
          "Affiliation": "Department of Cancer Medicine, University of Paris Saclay, Villejuif, France."
        },
        {
          "Identifier": "1947P",
          "Title": "Phase II study of sacituzumab govitecan (SG), domvanalimab (dom), and zimberelimab (zim) in metastatic non-small cell lung cancer (mNSCLC): VELOCITY-Lung substudy-01",
          "Speakers": "Alona Zer",
          "Affiliation": "Institute of Oncology, Rambam Health Campus, Haifa, Israel."
        },
        {
          "Identifier": "1018eTiP",
          "Title": "A phase I trial of RGT-61159, an oral MYB transcription factor inhibitor, for patients with relapsed/refractory (R/R) adenoid cystic carcinoma (ACC) and colorectal cancer (CRC)",
          "Speakers": "Renata Ferrarotto",
          "Affiliation": "The University of Texas Anderson Cancer Center, Houston, Texas, USA."
        },
        {
          "Identifier": "1019eTiP",
          "Title": "A phase I, multi-center, open-label, dose escalation and expansion study of AST-201 in patients with GPC3-positive advanced solid tumors",
          "Speakers": "Hong Jae Chon",
          "Affiliation": "Department of Medical Oncology, CHA Bundang Medical Center, CHA University, Seongnam"
        },
        {
          "Identifier": "1709MO",
          "Title": "Multi-center NCI-sponsored phase I study of triapine in combination with 177Lu-dotatate in patients with well-differentiated gastroenteropancreatic neuroendocrine tumours (GEP-NETs)",
          "Speakers": "Aman Chauhan",
          "Affiliation": "Division of Medical Oncology, Department of Medicine, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA."
        },
        {
          "Identifier": "2316P",
          "Title": "Global distribution and characteristics of research facilities recruiting for phase III oncology trials: Cross-sectional analysis",
          "Speakers": "Amanda F. Villarino",
          "Affiliation": ""
        },
        {
          "Identifier": "1348MO",
          "Title": "SKYSCRAPER-09: Phase II, randomised study of tiragolumab (tira) + atezolizumab (atezo) and atezo + placebo (pbo) as first-line (1L) treatment in patients (pts) with recurrent/metastatic PD-L1+ squamous cell carcinoma of the head and neck (R/M SCCHN)",
          "Speakers": "Amanda Psyrri",
          "Affiliation": "Medical Oncology Unit, 2nd Department of Internal Medicine-Propaedeutic, Medical School, National and Kapodistrian University of Athens, Attikon University Hospital, Chaidari, Greece."
        },
        {
          "Identifier": "781P",
          "Title": "Prognostic factors in locally advanced rectal cancer (LARC) in the ISANOX Trial: Report from a phase II trial",
          "Speakers": "Amina Mokrani",
          "Affiliation": ""
        },
        {
          "Identifier": "780P",
          "Title": "Updated results of the ISANOX phase II trial: Neoadjuvant chemotherapy with FOLFIRINOX and short-course radiotherapy in locally advanced rectal cancer",
          "Speakers": "Amina Mokrani",
          "Affiliation": ""
        },
        {
          "Identifier": "1065MO",
          "Title": "First-in-human study of AZD5335, a folate receptor  (FR)-targeted antibody-drug conjugate, in patients with platinum-resistant recurrent ovarian cancer",
          "Speakers": "Ana Oaknin",
          "Affiliation": "Medical Oncology Service, Vall d'Hebron Institute of Oncology, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain."
        },
        {
          "Identifier": "107eP",
          "Title": "Safety of ivosidenib in patients with mIDH1 CCA: Updated results from the phase IIIb ProvIDHe study",
          "Speakers": "Andrea Casadei Gardini",
          "Affiliation": "Department of Medical Oncology, San Raffaele Scientific Institute IRCCS, Milan, Italy."
        },
        {
          "Identifier": "677P",
          "Title": "EGFR-BPI: A novel prognostic tool for EGFR-mutated NSCLC with brain metastases",
          "Speakers": "Andreas V. Koulouris",
          "Affiliation": "University of Crete, 70013 Heraklion, Greece."
        }
      ]
    },
    "table_context": "**BIOMARKER/MOA TABLE:**\n| Biomarker/MOA   |   # Studies | Identifiers                                                                          | Sessions                                                 |\n|:----------------|------------:|:-------------------------------------------------------------------------------------|:---------------------------------------------------------|\n| HER2            |         215 | 523P, 1015eTiP, 572P, , 219eP, 447eP, 520P, 294MO, 336P, 478P, +205 more             | Poster, ePoster, Industry-Sponsored S, +3 more           |\n| EGFR            |          68 | 1948P, 853P, 677P, 2071eP, 891eP, LBA33, 3029eP, 2064eP, 249eP, , +58 more           | Poster, ePoster, Proffered Paper, +2 more                |\n| PD-L1           |          53 | 1017eTiP, 1348MO, 1323MO, 1578P, 1879P, 1515MO, LBA48, 1795P, 200eP, LBA22, +43 more | ePoster, Mini Oral Session, Poster, +2 more              |\n| ctDNA           |          53 | 1634P, 194eP, 2783P, 2609P, 335P, 801P, 1893P, 732MO, 2521eP, 1132P, +43 more        | Poster, ePoster, Mini Oral Session, +1 more              |\n| PD-1            |          47 | 1665P, LBA94, LBA61, 1564P, 2154P, 1372P, 1853MO, 1563P, 1545P, 2119P, +37 more      | Poster, Proffered Paper, Mini Oral Session, +1 more      |\n| BRAF            |          43 | 2996P, 853P, 1682P, 891eP, , 687P, 1646P, , 2991P, 803P, +33 more                    | Poster, ePoster, Industry-Sponsored S, +2 more           |\n| CDK4            |          38 | 523P, 1730P, , 507P, 498P, 532P, 649eP, 497P, 486MO, 513P, +28 more                  | Poster, Industry-Sponsored S, ePoster, +1 more           |\n| KRAS            |          33 | LBA84, 1016eTiP, 265eP, 1990P, 915O, , 1992P, 3029eP, 882eP, 743P, +23 more          | Proffered Paper, ePoster, Poster, +3 more                |\n| CDK4/6          |          30 | 1730P, 507P, 532P, 649eP, 497P, 486MO, 513P, 372P, 522P, 500P, +20 more              | Poster, ePoster, Mini Oral Session                       |\n| ALK             |          23 | 972P, 1984P, 1828P, 1983P, LBA66, 996P, 1982P, 2567P, , 1979P, +13 more              | Poster, Mini Oral Session, Industry-Sponsored S, +2 more |\n| MSI             |          23 | 3058eP, 858P, 1756eP, 1529P, 801P, 802P, , , 2111P, 872eP, +13 more                  | ePoster, Poster, Industry-Sponsored S, +3 more           |\n| dMMR            |          17 | 3058eP, 1529P, 752P, , , 872eP, , 724O, 2168P, 925MO, +7 more                        | ePoster, Poster, Industry-Sponsored S, +3 more           |\n| BRCA            |          16 | 942P, 2463P, 2363P, 1071P, 3181eP, 500P, 2228P, 3059eP, 2805MO, 330P, +6 more        | Poster, ePoster, Mini Oral Session, +1 more              |\n| MET             |          16 | 928P, 2074eP, 995P, 1795P, 1996P, 1967P, 1997P, 2610MO, 1955P, 932P, +6 more         | Poster, ePoster, Mini Oral Session, +1 more              |\n| BRCA1           |          14 | 942P, 3181eP, 1107P, 328P, 325P, 329P, 943P, 327P, 330P, 275eP, +4 more              | Poster, ePoster                                          |\n| VEGF            |          14 | 1017eTiP, , 1545P, 1466eTiP, 3049eP, 1860P, 792P, 1539P, 875eP, 1151P, +4 more       | ePoster, Industry-Sponsored S, Poster, +1 more           |\n| MSI-H           |          12 | 1529P, 802P, , , 2111P, 872eP, 230eP, 925MO, 2141P, LBA29, +2 more                   | Poster, Industry-Sponsored S, ePoster, +2 more           |\n| PIK3CA          |          12 | 219eP, 529P, 526P, 735P, 116MO, 530P, 598P, LBA17, 619TiP, 548P, +2 more             | ePoster, Poster, Mini Oral Session, +1 more              |\n| PARP            |          11 | 3147P, LBA45, 157P, 1093P, 1077P, 1338P, 2451P, 2270eP, 1133P, , +1 more             | Poster, Mini Oral Session, ePoster, +1 more              |\n| HRD             |          10 | , 326P, 1071P, 1146P, 1138P, 1130P, 471P, 1200P, 2731P, 1137P                        | Educational Session, Poster                              |\n| CLDN18.2        |           9 | 945P, 2136P, 2137P, , , , LBA83, 2139P, 2138P                                        | Poster, Industry-Sponsored S, Mini Oral Session          |\n| FGFR            |           8 | 1766eP, 284eP, 81MO, 1931P, 1932P, 288eTiP, 930P, 1456eP                             | ePoster, Mini Oral Session, Poster                       |\n| Nectin-4        |           7 | 967P, 3095P, 963P, 1013eP, 3100P, 1412P, 3105P                                       | Poster, ePoster                                          |\n| DLL3            |           7 | 1707MO, , 1731TiP, , 2776P, , 2775P                                                  | Mini Oral Session, Industry-Sponsored S, Poster          |\n| ERBB2           |           6 | 3102P, 3095P, 1146P, 348P, 2174P, 2003P                                              | Poster                                                   |\n| CTLA-4          |           6 | 1545P, 1685TiP, 1640P, 18P, 48eP,                                                    | Poster, ePoster, Symposium                               |\n| PI3K            |           6 | 1730P, LBA26, 466P, 619TiP, 602P, 195eP                                              | Poster, Mini Oral Session, ePoster                       |\n| TIGIT           |           5 | 1853MO, 1639P, 3061eP, 1885P, 1415P                                                  | Mini Oral Session, Poster, ePoster                       |\n| Claudin 18.2    |           4 | 2144P, 2113P, 1725P, 2139P                                                           | Poster                                                   |\n| NTRK            |           4 | 2013P, 171P, 687P, 2998P                                                             | Poster                                                   |\n| ROS1            |           4 | 1988P, 1986P, 2027TiP, 1987MO                                                        | Poster, Mini Oral Session                                |\n| IDH1            |           4 | 2749eP, 695P, 2748eP, 2745eP                                                         | ePoster, Poster                                          |\n| CTC             |           4 | LBA80, 190eP, 2394P, 1813eP                                                          | Proffered Paper, ePoster, Poster                         |\n| FGFR3           |           3 | 3070MO, 3102P, 3098P                                                                 | Mini Oral Session, Poster                                |\n| AKT             |           3 | 504P, 602P, 2701P                                                                    | Poster                                                   |\n| TMB             |           3 | 139P, 1713P, 1980P                                                                   | Poster                                                   |\n| B7-H3           |           3 | 950P, 2720P, 958P                                                                    | Poster                                                   |\n| DDR             |           3 | , 988P,                                                                              | Symposium, Poster, Educational Session                   |\n| RET             |           3 | 1999P, 2000P, 2998P                                                                  | Poster                                                   |\n| HER3            |           3 | 1142P, 921MO, 933P                                                                   | Poster, Mini Oral Session                                |\n| TROP-2          |           2 | 375P, 653eTiP                                                                        | Poster, ePoster                                          |\n| FGFR2           |           2 | 140P, 2158P                                                                          | Poster                                                   |\n| mTOR            |           2 | 226eP, 652eTiP                                                                       | ePoster                                                  |\n| CD19            |           2 | 1240O, 1246MO                                                                        | Proffered Paper, Mini Oral Session                       |\n| CEACAM5         |           2 | 65eP, 962P                                                                           | ePoster, Poster                                          |\n| NRG1            |           2 | 194eP, 1993P                                                                         | ePoster, Poster                                          |\n| ATR             |           2 | 939P, 618TiP                                                                         | Poster                                                   |\n| VEGFR           |           2 | 2607P, 214eP                                                                         | Poster, ePoster                                          |\n| BRCA2           |           2 | 1145P, 328P                                                                          | Poster                                                   |\n| LAG-3           |           1 | 1857P                                                                                | Poster                                                   |\n| FGFR1           |           1 | 2067eP                                                                               | ePoster                                                  |\n| ATM             |           1 | 472P                                                                                 | Poster                                                   |\n| VEGFR2          |           1 | 195eP                                                                                | ePoster                                                  |\n| WNT             |           1 | 2713P                                                                                | Poster                                                   |\n| CD38            |           1 | 1290P                                                                                | Poster                                                   |\n| IDH2            |           1 | 2748eP                                                                               | ePoster                                                  |\n| CD20            |           1 | 1298eP                                                                               | ePoster                                                  |\n| NaPi2b          |           1 | LBA43                                                                                | Mini Oral Session                                        |\n\n**NOVEL/EARLY-PHASE STUDIES:**\n| Identifier   | Title                                                                                                                                                                                                                                                                                     | Speakers                    | Affiliation                                                                                                                                                                                      |\n|:-------------|:------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|:----------------------------|:-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n| 2388P        | Results from the phase Ib dose escalation of 212Pb-ADVC001 in PSMA-positive metastatic castration-resistant prostate cancer (mCRPC): The theraPb trial                                                                                                                                    | Aaron R. Hansen             | Department of Medicine, University of Queensland, Brisbane, QLD 4072, Australia.                                                                                                                 |\n| 775P         | Sequencing neoadjuvant chemotherapy and short course radiation therapy in locally advanced rectal cancer: A phase II randomized controlled trial [SPADE study]                                                                                                                            | Abhishek Shinghal           | Department of Radiation Oncology, Mahamana Pandit Madan Mohan Malaviya Cancer Centre and Homi Bhabha Cancer Hospital, Tata Memorial Centre, Homi Bhabha National Institute, Varanasi, India.     |\n| 2604P        | Farnesyltransferase inhibitor (FTI) KO-2806 in combination with cabozantinib (cabo) in renal cell carcinoma (RCC): Preliminary results from FIT-001 phase I trial                                                                                                                         | Adanma Ayanambakkam         | University of Oklahoma Stephenson Cancer Center, OK                                                                                                                                              |\n| 1000TiP      | Novel next generation PARP1-selective and CNS penetrant inhibitor DSB2455: A phase Ia/Ib open label, multi-centre dose escalation study with expansion cohorts to assess the safety, tolerability, and activity as monotherapy in participants with advanced malignancies                 | Ramon Yarza                 | START-CIOCC, University Hospital HM Sanchinarro, Madrid, Spain.                                                                                                                                  |\n| 1001TiP      | Raludotatug deruxtecan in participants with gastrointestinal cancers: Phase II REJOICE-GI01 trial                                                                                                                                                                                         | Makoto Ueno                 | Department of Gastroenterology, Hepatobiliary and Pancreatic Medical Oncology Division Kanagawa Cancer Center Yokohama Japan.                                                                    |\n| 1015eTiP     | Beamion BCGC-1: A phase Ib/II, randomized, open-label, multicenter trial of oral zongertinib, alone or in combination, for the treatment of advanced HER2-positive metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | Sara A. Hurvitz             | University of Washington Fred Hutchinson Cancer Center, Seattle, WA, USA.                                                                                                                        |\n| 1337P        | Dose-finding and efficacy confirmation trial of the superselective intra-arterial cisplatin and concomitant radiotherapy for locally advanced maxillary sinus cancer (JCOG1212): Results of the efficacy confirmation phase in the T4b cohort                                             | Akihiro Homma               | Department of Otolaryngology-Head & Neck Surgery, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan.                                                      |\n| 1016eTiP     | A first-in-human phase I study of LY4066434, a potent and orally bioavailable pan-KRAS inhibitor, in KRAS-mutant solid tumors (Trial in Progress)                                                                                                                                         | Shigehisa Kitano            | Department of Advanced Medical Development, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.                                                              |\n| 2227P        | Safety and clinical efficacy of cambritaxestat (IOA-289), a novel autotaxin inhibitor, plus gemcitabine and nab-paclitaxel (GnP) in patients with previously untreated metastatic pancreatic ductal adenocarcinoma (mPDAC)                                                                | Alberto Quinzii             | Digestive Molecular Clinical Oncology Research Unit, Verona, Italy.                                                                                                                              |\n| 1485P        | Atezolizumab plus bevacizumab before or after transarterial chemoembolization in hepatocellular carcinoma: Interim analysis of the DEMAND (AIO-HEP-0418) randomized phase II clinical trial                                                                                               | Alexander B. Philipp        | Department of Medicine II, University Hospital, LMU Munich, Munich, Germany.                                                                                                                     |\n| 1017eTiP     | A phase II trial of DB-1311/BNT324 (B7H3 ADC) combined with BNT327 (PD-L1 x VEGF-A bsAb) or DB-1305/BNT325 (TROP2 ADC) in advanced/metastatic solid tumors                                                                                                                                | Ye Guo                      | Department of Oncology, Shanghai Dongfang Hospital, Tongji University, Shanghai, China.                                                                                                          |\n| 2023P        | Phase Ib study of valemetostat in combination with datopotamab deruxtecan (Dato-DXd) in advanced non-squamous non-small cell lung cancer (NSCLC): Initial safety results                                                                                                                  | Alexander I. Spira          | Virginia Cancer Specialists, Fairfax, VA, USA.                                                                                                                                                   |\n| 1611P        | Pembrolizumab versus placebo as adjuvant therapy for resected stage IIB or IIC melanoma: 5-year follow-up of the phase III KEYNOTE-716 study                                                                                                                                              | Alexander M. Eggermont      | University Medical Center Utrecht & Princess Maxima Center, Utrecht, Netherlands, Comprehensive Cancer Center Munchen of the Technical University Munich & Ludwig Maximilians University, Munich |\n| 3070MO       | Phase I study of LY3866288, a potent, highly isoform-selective FGFR3 inhibitor in FGFR3-altered advanced solid tumors (FORAGER-1): Dose optimization                                                                                                                                      | Alexandra Drakaki           | 19University of California, Los Angeles Medical Center, CA, USA.                                                                                                                                 |\n| 853P         | Landscape of anti-EGFR resistance mutations in RAS/BRAF-wild type left-sided metastatic colorectal cancer: First sequencing results of the phase III CRC01 prospective trial                                                                                                              | Alexandra Lebedeva          | Institute for Personalized Oncology, Sechenov First Moscow State Medical University, Moscow 119048, Russia.                                                                                      |\n| 2274O        | Dissecting four decades of phase III randomised pharmacological interventions for primary cancer prevention to guide future developments: ESMO early detection and prevention task force                                                                                                  | Alexandre Xu-Vuillard       | Gustave-Roussy, Villejuif, France, Sorbonne Université, Paris                                                                                                                                    |\n| 1038MO       | Single-dose carboplatin and involved-node radiotherapy for seminoma stage IIA/B: Long-term follow-up from the international multicenter phase II trial SAKK 01/10                                                                                                                         | Alexandros Papachristofilou | Department of Radiation Oncology, University Hospital Basel, Basel, Switzerland.                                                                                                                 |\n| 1083P        | Platinum-based vs non-platinum chemotherapy in platinum-resistant relapsed ovarian cancer (PROC): A randomized phase II trial                                                                                                                                                             | Alexey Rumyantsev           | N.N. Blokhin National Medical Research Center of Oncology, Moscow, Russia.                                                                                                                       |\n| 2445P        | Phase I/II study of gedatolisib in combination with darolutamide in metastatic castration-resistant prostate cancer (mCRPC)                                                                                                                                                               | Alice Bernard-Tessier       | Department of Cancer Medicine, University of Paris Saclay, Villejuif, France.                                                                                                                    |\n| 1947P        | Phase II study of sacituzumab govitecan (SG), domvanalimab (dom), and zimberelimab (zim) in metastatic non-small cell lung cancer (mNSCLC): VELOCITY-Lung substudy-01                                                                                                                     | Alona Zer                   | Institute of Oncology, Rambam Health Campus, Haifa, Israel.                                                                                                                                      |\n| 1018eTiP     | A phase I trial of RGT-61159, an oral MYB transcription factor inhibitor, for patients with relapsed/refractory (R/R) adenoid cystic carcinoma (ACC) and colorectal cancer (CRC)                                                                                                          | Renata Ferrarotto           | The University of Texas Anderson Cancer Center, Houston, Texas, USA.                                                                                                                             |\n| 1019eTiP     | A phase I, multi-center, open-label, dose escalation and expansion study of AST-201 in patients with GPC3-positive advanced solid tumors                                                                                                                                                  | Hong Jae Chon               | Department of Medical Oncology, CHA Bundang Medical Center, CHA University, Seongnam                                                                                                             |\n| 1709MO       | Multi-center NCI-sponsored phase I study of triapine in combination with 177Lu-dotatate in patients with well-differentiated gastroenteropancreatic neuroendocrine tumours (GEP-NETs)                                                                                                     | Aman Chauhan                | Division of Medical Oncology, Department of Medicine, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA.                                                                |\n| 2316P        | Global distribution and characteristics of research facilities recruiting for phase III oncology trials: Cross-sectional analysis                                                                                                                                                         | Amanda F. Villarino         |                                                                                                                                                                                                  |\n| 1348MO       | SKYSCRAPER-09: Phase II, randomised study of tiragolumab (tira) + atezolizumab (atezo) and atezo + placebo (pbo) as first-line (1L) treatment in patients (pts) with recurrent/metastatic PD-L1+ squamous cell carcinoma of the head and neck (R/M SCCHN)                                 | Amanda Psyrri               | Medical Oncology Unit, 2nd Department of Internal Medicine-Propaedeutic, Medical School, National and Kapodistrian University of Athens, Attikon University Hospital, Chaidari, Greece.          |\n| 781P         | Prognostic factors in locally advanced rectal cancer (LARC) in the ISANOX Trial: Report from a phase II trial                                                                                                                                                                             | Amina Mokrani               |                                                                                                                                                                                                  |\n| 780P         | Updated results of the ISANOX phase II trial: Neoadjuvant chemotherapy with FOLFIRINOX and short-course radiotherapy in locally advanced rectal cancer                                                                                                                                    | Amina Mokrani               |                                                                                                                                                                                                  |\n| 1065MO       | First-in-human study of AZD5335, a folate receptor  (FR)-targeted antibody-drug conjugate, in patients with platinum-resistant recurrent ovarian cancer                                                                                                                                   | Ana Oaknin                  | Medical Oncology Service, Vall d'Hebron Institute of Oncology, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.                                                                        |\n| 107eP        | Safety of ivosidenib in patients with mIDH1 CCA: Updated results from the phase IIIb ProvIDHe study                                                                                                                                                                                       | Andrea Casadei Gardini      | Department of Medical Oncology, San Raffaele Scientific Institute IRCCS, Milan, Italy.                                                                                                           |\n| 677P         | EGFR-BPI: A novel prognostic tool for EGFR-mutated NSCLC with brain metastases                                                                                                                                                                                                            | Andreas V. Koulouris        | University of Crete, 70013 Heraklion, Greece.                                                                                                                                                    |\n"
  },
  "renal_cancer": {
    "regimen_groups": [
      {
        "regimen": "Cabozantinib",
        "count": 6,
        "examples": [
          "2604P",
          "2646P",
          "LBA94",
          "2651P",
          "2626P"
        ]
      }
    ],
    "unmet_need_signals": [
      {
        "category": "Post-progression",
        "count": 4
      },
      {
        "category": "Resistance mechanisms",
        "count": 2
      },
      {
        "category": "Elderly patients",
        "count": 1
      },
      {
        "category": "Sequencing strategies",
        "count": 1
      }
    ],
    "biomarker_moa": {
      "columns": [
        "Biomarker/MOA",
        "# Studies",
        "Identifiers",
        "Sessions"
      ],
      "rows": [
        {
          "Biomarker/MOA": "PD-1",
          "# Studies": 4,
          "Identifiers": "LBA94, 1530P, 2660eP, 2634P",
          "Sessions": "Proffered Paper, Poster, ePoster"
        },
        {
          "Biomarker/MOA": "ctDNA",
          "# Studies": 2,
          "Identifiers": "2609P, 2660eP",
          "Sessions": "Poster, ePoster"
        },
        {
          "Biomarker/MOA": "FGFR3",
          "# Studies": 1,
          "Identifiers": "3070MO",
          "Sessions": "Mini Oral Session"
        },
        {
          "Biomarker/MOA": "MET",
          "# Studies": 1,
          "Identifiers": "2610MO",
          "Sessions": "Mini Oral Session"
        },
        {
          "Biomarker/MOA": "VEGFR",
          "# Studies": 1,
          "Identifiers": "2607P",
          "Sessions": "Poster"
        }
      ]
    },
    "novel_studies": {
      "columns": [
        "Identifier",
        "Title",
        "Speakers",
        "Affiliation"
      ],
      "rows": [
        {
          "Identifier": "2604P",
          "Title": "Farnesyltransferase inhibitor (FTI) KO-2806 in combination with cabozantinib (cabo) in renal cell carcinoma (RCC): Preliminary results from FIT-001 phase I trial",
          "Speakers": "Adanma Ayanambakkam",
          "Affiliation": "University of Oklahoma Stephenson Cancer Center, OK"
        },
        {
          "Identifier": "3070MO",
          "Title": "Phase I study of LY3866288, a potent, highly isoform-selective FGFR3 inhibitor in FGFR3-altered advanced solid tumors (FORAGER-1): Dose optimization",
          "Speakers": "Alexandra Drakaki",
          "Affiliation": "19University of California, Los Angeles Medical Center, CA, USA."
        },
        {
          "Identifier": "LBA94",
          "Title": "LenCabo: A randomized phase II multicenter trial of lenvatinib plus everolimus (len/eve) versus (vs) cabozantinib (cabo) in patients (pts) with metastatic clear cell RCC (ccRCC) that progressed on PD-1 immune checkpoint inhibition (ICI)",
          "Speakers": "Andrew W. Hahn",
          "Affiliation": "Department of Genitourinary Medical Oncology, The University of Texas Anderson Cancer Center, Houston, TX, USA."
        },
        {
          "Identifier": "",
          "Title": "Beyond the Basics: Novel Therapies in Renal Cell Carcinoma",
          "Speakers": "Brian I. Rini",
          "Affiliation": "Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN, USA."
        },
        {
          "Identifier": "2625P",
          "Title": "Efficacy of [177Lu]Lu-PSMA-617 in patients with metastatic clear cell renal cell carcinoma: A multicentre single-arm phase II trial (RENALUT)",
          "Speakers": "Emmanuel Seront",
          "Affiliation": "Department of Medical Oncology, Brussels, Belgium."
        },
        {
          "Identifier": "LBA95",
          "Title": "Neoadjuvant immunotherapy in locally advanced clear cell renal cell carcinoma at risk for recurrence or distant metastases: the randomized phase II NESCIO trial",
          "Speakers": "Femke Burgers",
          "Affiliation": "Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam"
        },
        {
          "Identifier": "2861P",
          "Title": "Safety and preliminary efficacy of Meldonium in metastatic renal cell carcinoma (mRCC) patients with treatment-related fatigue: Phase 1/2 study results",
          "Speakers": "Ilya Tsimafeyeu",
          "Affiliation": "Russian Society of Clinical Oncology, Kidney Cancer Research Bureau, Moscow, Russia."
        },
        {
          "Identifier": "2623P",
          "Title": "CLEAR-IT: Preliminary results from a phase II study evaluating Cadonilimab plus Lenvatinib in previously immunotherapy-treated advanced/metastatic clear cell renal cell carcinoma (ccRCC)",
          "Speakers": "Jiwei Huang",
          "Affiliation": "Department of Urology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China."
        },
        {
          "Identifier": "2596MO",
          "Title": "Phase Ib/II trial of ipilimumab, nivolumab, and ciforadenant (adenosine A2a receptor antagonist) in first-line advanced renal cell carcinoma (RCC), a kidney cancer research consortium study",
          "Speakers": "Kathryn Beckermann",
          "Affiliation": "Greco-Hainsworth Center for Cancer Research, Nashville, TN, USA."
        },
        {
          "Identifier": "2621P",
          "Title": "Efficacy and safety of adjuvant penpulimab in very high-risk clear cell renal cell carcinoma: A prospective, controlled, phase II study",
          "Speakers": "Liangyou Gu",
          "Affiliation": "Department of Urology, The Third Medical Center, Chinese PLA General Hospital, Beijing, China."
        },
        {
          "Identifier": "2662eP",
          "Title": "A novel granulocyte scoring system for use as a predictive/prognostic biomarker in patients with renal cell carcinoma (RCC) undergoing treatment with combination immunotherapy",
          "Speakers": "Maximilian Julve",
          "Affiliation": "The Royal Marsden Hospital."
        },
        {
          "Identifier": "2682eTiP",
          "Title": "EXPLORE-RCC: A phase II study of neoadjuvant zanzalintinib (ZANZA) plus nivolumab (NIVO) in patients with locally advanced and/or inoperable clear cell renal cell carcinoma (ccRCC)",
          "Speakers": "Qian Qin",
          "Affiliation": "Department of Internal Medicine, University of Texas, Southwestern Medical Center, Dallas, Texas."
        },
        {
          "Identifier": "2683eTiP",
          "Title": "TEM-GU: A phase I/II clinical study of a genetically-modified Tie-2 expressing monocytes in patients with metastatic renal cell carcinoma",
          "Speakers": "Chiara Mercinelli",
          "Affiliation": "Department of Medical Oncology, IRCCS San Raffaele Hospital, Milan, Italy, Unit of Medical Oncology 2, Pisa, Italy."
        },
        {
          "Identifier": "2648P",
          "Title": "Phase II clinical study of the safety and efficacy of Sintilimab in combination with Axitinib and stereotactic radiotherapy in the treatment of local-regional recurrent renal cell carcinoma",
          "Speakers": "Pei Dong",
          "Affiliation": "Department of Urology Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou, China."
        },
        {
          "Identifier": "2602P",
          "Title": "Safety and efficacy of iparomlimab and tuvonralimab (QL1706) plus lenvatinib in previously untreated patients with clear cell renal cell carcinoma: Results from a phase Ib study",
          "Speakers": "Pei Dong",
          "Affiliation": "Department of Urology Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou, China."
        },
        {
          "Identifier": "2601P",
          "Title": "Peripheral and tumor cytokines in exceptional responders to immunotherapy: Results from a phase III trial",
          "Speakers": "Renee M. Saliby",
          "Affiliation": "Dana-Farber Cancer Institute, Boston, Massachusetts, USA."
        },
        {
          "Identifier": "2591O",
          "Title": "Efficacy of cabozantinib and nivolumab in cluster 1/2 metastatic clear cell renal cell carcinoma: Results from OPTIC RCC, a phase II trial of a novel RNAseq-based biomarker",
          "Speakers": "Scott M. Haake",
          "Affiliation": "Division of Hematology and Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN"
        },
        {
          "Identifier": "2617P",
          "Title": "Coaching of renal cell cancer patients on side effects of systemic cancer treatment: Lessons from the phase III PREPARE trial [PREPARE; AIO-NZK-0115/ass; IAG-N]",
          "Speakers": "Viktor Gruenwald",
          "Affiliation": "Department of Hematology, Hemostasis, Oncology, Hannover Medical School, Carl-Neuberg-Str. 1, D-30625 Hannover, Germany."
        },
        {
          "Identifier": "2592MO",
          "Title": "Fruquintinib (FRUQ) plus sintilimab (SIN) versus axitinib (AXI) or everolimus (EVE) monotherapy as 2L treatment in pts with locally advanced or metastatic renal cell carcinoma (RCC): Results from phase III part of a randomized, open-label, active-controlled phase II/III study (FRUSICA-2)",
          "Speakers": "Zhenhua Liu",
          "Affiliation": "Department of Abdominal Surgery, Ganzhou Cancer Hospital, Ganzhou, China."
        }
      ]
    },
    "table_context": "**BIOMARKER/MOA TABLE:**\n| Biomarker/MOA   |   # Studies | Identifiers                 | Sessions                         |\n|:----------------|------------:|:----------------------------|:---------------------------------|\n| PD-1            |           4 | LBA94, 1530P, 2660eP, 2634P | Proffered Paper, Poster, ePoster |\n| ctDNA           |           2 | 2609P, 2660eP               | Poster, ePoster                  |\n| FGFR3           |           1 | 3070MO                      | Mini Oral Session                |\n| MET             |           1 | 2610MO                      | Mini Oral Session                |\n| VEGFR           |           1 | 2607P                       | Poster                           |\n\n**NOVEL/EARLY-PHASE STUDIES:**\n| Identifier   | Title                                                                                                                                                                                                                                                                                            | Speakers            | Affiliation                                                                                                                                                                                  |\n|:-------------|:-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|:--------------------|:---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n| 2604P        | Farnesyltransferase inhibitor (FTI) KO-2806 in combination with cabozantinib (cabo) in renal cell carcinoma (RCC): Preliminary results from FIT-001 phase I trial                                                                                                                                | Adanma Ayanambakkam | University of Oklahoma Stephenson Cancer Center, OK                                                                                                                                          |\n| 3070MO       | Phase I study of LY3866288, a potent, highly isoform-selective FGFR3 inhibitor in FGFR3-altered advanced solid tumors (FORAGER-1): Dose optimization                                                                                                                                             | Alexandra Drakaki   | 19University of California, Los Angeles Medical Center, CA, USA.                                                                                                                             |\n| LBA94        | LenCabo: A randomized phase II multicenter trial of lenvatinib plus everolimus (len/eve) versus (vs) cabozantinib (cabo) in patients (pts) with metastatic clear cell RCC (ccRCC) that progressed on PD-1 immune checkpoint inhibition (ICI)                                                     | Andrew W. Hahn      | Department of Genitourinary Medical Oncology, The University of Texas Anderson Cancer Center, Houston, TX, USA.                                                                              |\n|              | Beyond the Basics: Novel Therapies in Renal Cell Carcinoma                                                                                                                                                                                                                                       | Brian I. Rini       | Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN, USA.                                                                                                   |\n| 2625P        | Efficacy of [177Lu]Lu-PSMA-617 in patients with metastatic clear cell renal cell carcinoma: A multicentre single-arm phase II trial (RENALUT)                                                                                                                                                    | Emmanuel Seront     | Department of Medical Oncology, Brussels, Belgium.                                                                                                                                           |\n| LBA95        | Neoadjuvant immunotherapy in locally advanced clear cell renal cell carcinoma at risk for recurrence or distant metastases: the randomized phase II NESCIO trial                                                                                                                                 | Femke Burgers       | Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam                                                                                                                      |\n| 2861P        | Safety and preliminary efficacy of Meldonium in metastatic renal cell carcinoma (mRCC) patients with treatment-related fatigue: Phase 1/2 study results                                                                                                                                          | Ilya Tsimafeyeu     | Russian Society of Clinical Oncology, Kidney Cancer Research Bureau, Moscow, Russia.                                                                                                         |\n| 2623P        | CLEAR-IT: Preliminary results from a phase II study evaluating Cadonilimab plus Lenvatinib in previously immunotherapy-treated advanced/metastatic clear cell renal cell carcinoma (ccRCC)                                                                                                       | Jiwei Huang         | Department of Urology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.                                                                                   |\n| 2596MO       | Phase Ib/II trial of ipilimumab, nivolumab, and ciforadenant (adenosine A2a receptor antagonist) in first-line advanced renal cell carcinoma (RCC), a kidney cancer research consortium study                                                                                                    | Kathryn Beckermann  | Greco-Hainsworth Center for Cancer Research, Nashville, TN, USA.                                                                                                                             |\n| 2621P        | Efficacy and safety of adjuvant penpulimab in very high-risk clear cell renal cell carcinoma: A prospective, controlled, phase II study                                                                                                                                                          | Liangyou Gu         | Department of Urology, The Third Medical Center, Chinese PLA General Hospital, Beijing, China.                                                                                               |\n| 2662eP       | A novel granulocyte scoring system for use as a predictive/prognostic biomarker in patients with renal cell carcinoma (RCC) undergoing treatment with combination immunotherapy                                                                                                                  | Maximilian Julve    | The Royal Marsden Hospital.                                                                                                                                                                  |\n| 2682eTiP     | EXPLORE-RCC: A phase II study of neoadjuvant zanzalintinib (ZANZA) plus nivolumab (NIVO) in patients with locally advanced and/or inoperable clear cell renal cell carcinoma (ccRCC)                                                                                                             | Qian Qin            | Department of Internal Medicine, University of Texas, Southwestern Medical Center, Dallas, Texas.                                                                                            |\n| 2683eTiP     | TEM-GU: A phase I/II clinical study of a genetically-modified Tie-2 expressing monocytes in patients with metastatic renal cell carcinoma                                                                                                                                                        | Chiara Mercinelli   | Department of Medical Oncology, IRCCS San Raffaele Hospital, Milan, Italy, Unit of Medical Oncology 2, Pisa, Italy.                                                                          |\n| 2648P        | Phase II clinical study of the safety and efficacy of Sintilimab in combination with Axitinib and stereotactic radiotherapy in the treatment of local-regional recurrent renal cell carcinoma                                                                                                    | Pei Dong            | Department of Urology Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou, China. |\n| 2602P        | Safety and efficacy of iparomlimab and tuvonralimab (QL1706) plus lenvatinib in previously untreated patients with clear cell renal cell carcinoma: Results from a phase Ib study                                                                                                                | Pei Dong            | Department of Urology Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou, China. |\n| 2601P        | Peripheral and tumor cytokines in exceptional responders to immunotherapy: Results from a phase III trial                                                                                                                                                                                        | Renee M. Saliby     | Dana-Farber Cancer Institute, Boston, Massachusetts, USA.                                                                                                                                    |\n| 2591O        | Efficacy of cabozantinib and nivolumab in cluster 1/2 metastatic clear cell renal cell carcinoma: Results from OPTIC RCC, a phase II trial of a novel RNAseq-based biomarker                                                                                                                     | Scott M. Haake      | Division of Hematology and Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN                                                                             |\n| 2617P        | Coaching of renal cell cancer patients on side effects of systemic cancer treatment: Lessons from the phase III PREPARE trial [PREPARE; AIO-NZK-0115/ass; IAG-N]                                                                                                                                 | Viktor Gruenwald    | Department of Hematology, Hemostasis, Oncology, Hannover Medical School, Carl-Neuberg-Str. 1, D-30625 Hannover, Germany.                                                                     |\n| 2592MO       | Fruquintinib (FRUQ) plus sintilimab (SIN) versus axitinib (AXI) or everolimus (EVE) monotherapy as 2L treatment in pts with locally advanced or metastatic renal cell carcinoma (RCC): Results from phase III part of a randomized, open-label, active-controlled phase II/III study (FRUSICA-2) | Zhenhua Liu         | Department of Abdominal Surgery, Ganzhou Cancer Hospital, Ganzhou, China.                                                                                                                    |\n"
  },
  "merkel_cell": {
    "regimen_groups": [],
    "unmet_need_signals": [],
    "novel_studies": {
      "columns": [
        "Identifier",
        "Title",
        "Speakers",
        "Affiliation"
      ],
      "rows": [
        {
          "Identifier": "LBA56",
          "Title": "ECOG-ACRIN EA6174: STAMP: Surgically Treated Adjuvant Merkel Cell Carcinoma with Pembrolizumab, a Phase III Trial",
          "Speakers": "Janice M. Mehnert",
          "Affiliation": "Melanoma and Cutaneous Medical Oncology, Perlmutter Cancer Center, NY University, Langone Health"
        },
        {
          "Identifier": "1739eTiP",
          "Title": "Chemio-immunotherapy in nai ve advanced Merkel cell carcinoma (MCC): The phase II PANDORA trial",
          "Speakers": "Simone Oldani",
          "Affiliation": "Medical Oncology Department, Milan, Italy."
        }
      ]
    },
    "table_context": "**NOVEL/EARLY-PHASE STUDIES:**\n| Identifier   | Title                                                                                                             | Speakers          | Affiliation                                                                                      |\n|:-------------|:------------------------------------------------------------------------------------------------------------------|:------------------|:-------------------------------------------------------------------------------------------------|\n| LBA56        | ECOG-ACRIN EA6174: STAMP: Surgically Treated Adjuvant Merkel Cell Carcinoma with Pembrolizumab, a Phase III Trial | Janice M. Mehnert | Melanoma and Cutaneous Medical Oncology, Perlmutter Cancer Center, NY University, Langone Health |\n| 1739eTiP     | Chemio-immunotherapy in nai ve advanced Merkel cell carcinoma (MCC): The phase II PANDORA trial                   | Simone Oldani     | Medical Oncology Department, Milan, Italy.                                                       |\n"
  }
}